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Summary 
Human African Trypanosomiasis (HAT) or African Sleeping Sickness is a disease 
prevalent in many parts of Sub-Saharan Africa.  HAT is a parasitic infection caused by 
two species, Trypanosoma brucei gambiense and T. b. rhodesiense.  Clinical diagnosis 
is not sufficient as symptoms from other endemic diseases, such as Malaria, are similar.  
Currently the diagnosis of T. b. gambiense infection mainly relies on the Card 
Agglutination Test for Trypanosomiasis (CATT), which has severe limitations. Other 
diagnostic tests for T. b. gambiense and T. b. rhodesiense infections require lab based 
equipment, trained personnel and have varying degrees of sensitivity and specificity.  
New approaches are needed, firstly to identify new diagnostic biomarkers, and secondly 
to find a more suitable platform for the test. 
 
Our aim was to develop a lateral flow test based on trypanosome antigens. We used sera 
from T. b. gambiense infected and non-infected patients to identify infection specific 
diagnostic trypanosome proteins. The trypanosome proteins identified were then cloned 
into E. coli for recombinant expression and purification. The recombinant proteins were 
then screened by ELISA against 145 patients’ sera from the WHO HAT specimen bank. 
Invariant Surface Glycoprotein (ISG) 65 and soluble Variant Surface Glycoprotein 
(VSG) 117 were selected for development into a lateral flow format and 80 randomised 
patients’ sera were used to evaluate these prototypes. Here we describe the results 
showing that un-optimised proto-type lateral flow tests match the reported CATT 
sensitivity and specificity scores.  
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1. Introduction 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is an 
infection caused by the single celled eukaryotic parasite Trypanosoma brucei (Barrett et 
al., 2003).  The two human infectious sub-species, T. b. gambiense and T. b. 
rhodesiense are the causative agents of two clinically distinct diseases, collectively 
defined as HAT (Welburn et al., 2001).  The parasites are prevalent throughout sub-
Saharan Africa and cause approximately 10,000 cases every year (Smith et al., 1998, 
Malvy and Chappuis, 2011) although various estimates predict this figure to be higher 
and it is more likely to affect 30,000 people annually (Bisser and Courtioux, 2012, 
Simarro et al., 2011, Brun et al., 2010).  
 
The T. b. gambiense infection is mainly found in West and Central Africa (Figure 1.1) 
and is the chronic form of the disease (Balmer et al., 2011) whereas, the T. b. 
rhodesiense infection is found in East and Southern Africa and mainly causes the acute 
form. (Balmer et al., 2011).  T. b. gambiense represents 90 to 95% of diagnosed cases, 
with T. b. rhodesiense representing the remaining cases (Simarro et al., 2010). 
Trypanosomes are transmitted mostly via the bite of an infected tsetse fly (Glossina 
genus).   
 
Current diagnosis of T. b. gambiense in the field mainly relies on the Card 
Agglutination Test for Trypanosomiasis (CATT). This has severe limitations which we 
hope to address in our work by designing a new lateral flow test for the diagnosis of 
HAT.  
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1.1. The history and epidemiology of HAT  
Trypanosoma brucei belongs to the Salivarian trypanosome group, which diverged from 
other trypanosomes approximately 300 million years ago and around this time they 
became gut parasites of early insects (Haag, 1998). It is postulated that the link between 
the tsetse fly and trypanosomes emerged around 35 million years ago (Steverding, 2008, 
Lambrecht, 1985). The link between HAT, the tsetse fly and T. brucei was relatively 
recently established. The physicians, John Aktins (1734) and Thomas Winterbottom 
(1803), identified the symptoms associated with HAT during the slave trade (Cox, 
2004).  The links between the causative agent, the cattle disease nagana, sleeping 
sickness and the transmission vector were collectively established by researchers from a 
range of fields including; David Livingston, David Bruce, Robert Michael Forde, 
Joseph Everett Dutton and Friedrich Karl Kleine, among others (Steverding, 2008).   
 
The T. b. gambiense form of the disease was identified and described by Joseph Everett 
Dutton, in the country known at the time as Gambia, which is now several different 
countries (Steverding, 2008). It was recognised to present with chronic symptoms and 
was mainly localised to West and Central Sub-Saharan Africa. Conversely the T. b. 
rhodesiense form was recognised in Northern Rhodesia, now known as Zambia in 1910 
by Stevens and Fantham (Cox, 2004) . The Rhodesian form of the disease was 
recognised to be acute and aggressive and mainly located in distinct foci in areas of East 
and Southern Africa (Gibson, 2005).  T. b. gambiense is more likely to be involved in 
epidemics due to its long human host cycles and vector feeding habits, which are the 
major determinants of transmission of the parasite (Pépin and Méda, 2001). Conversely, 
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the aggressive and acute nature of the rhodesiense trypanosome infections make the 
potential for epidemics less likely (Pépin and Méda, 2001).    
 
There have been three recorded epidemics of HAT in the 20th Century, with estimates of 
300,000 or more infected individuals (Simarro et al., 2011). By the 1960s, transmission 
and the number of cases were very low (Figure 1.2) and today the  number of recorded 
cases has dropped below 10,000 per year, however the prevalence of HAT is predicted 
to be higher due to under-reporting (Mumba et al., 2011).  HAT still continues to be a 
large burden on individuals and communities in terms of disability-adjusted life years 
(DALYs) (Simarro et al., 2010, Fèvre et al., 2008b). DALYs allow for the assessment 
of disease not only based on death but on morbidity and the impact of the disease on the 
individual and their community (Lutumba et al., 2007, Fèvre et al., 2008a). 
 
1.1.1. Control methods 
Since the disease’s identification the colonial authorities at the time set up extensive 
control operations, including systematic screening and treatment of T. b. gambiense 
infected individuals; while in areas endemic with T. b. rhodesiense, the main control 
methods included identifying animal reservoirs and attempting to control the vector, e.g. 
with tsetse traps (Simarro et al., 2011).  With the prospect of elimination in sight during 
the 1960s and 1970s, the high cost, seemingly few cases and political instability led to 
the decline in surveillance by public health officials in the affected countries 
(Steverding, 2008, Simarro et al., 2011).  Subsequently HAT numbers have risen and 
though it appears HAT is currently under control, there is a fear that events, such as 
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civil unrest or upheaval may serve as a catalyst for future epidemics (Welburn et al., 
2009, Tong et al., 2011b).  A large problem of HAT control relates to the geographical 
distribution of HAT, which is directly linked to the Tsetse fly belt. This currently ranges 
across many countries with a combined area of 8 million km2 (Steverding, 2008). The 
‘HAT atlas’ records and makes available locations of HAT foci which can inform 
screening and control strategies (Simarro et al., 2010, Simarro et al., 2011).  
 
1.1.2. HAT cases in non-endemic areas 
There have been a number of HAT cases diagnosed in non-endemic locations, mainly 
due to patients spending time in a HAT endemic location (Migchelsen et al., 2011, Wolf 
et al., 2012). In some cases patients were misdiagnosed and mistreated, usually for 
malaria and Toxoplasma gondii infections, because HAT patients have antibodies which 
cross-react with the diagnostic tests for the other infectious diseases or show 
inconclusive results (Sahlas et al., 2002). Approximately 60 % of cases diagnosed in 
non-endemic regions are caused by T. b. rhodesiense, while 40 % were infected with T. 
b. gambiense (Lejon et al., 2003). Travel to HAT endemic areas is likely to increase due 
to more accessible tourism, so there is a need for physicians and travellers to be made 
more aware of these diseases (Gautret et al., 2009).  
 
Typically HAT occurs in more rural locations however there is a growing concern that 
tsetse flies are becoming more prevalent in the urban setting, and it has been reported 
recently that some were carrying T. b. gambiense (Simon et al., 2012).  Another 
unknown factor is the potential effect of climate change on the tsetse fly belt, which has 
been predicted to increase the number of people at risk of HAT (Moore et al., 2012). 
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1.2. Trypanosoma brucei   
T. brucei is a unicellular protozoan parasite that belongs to the genus Trypanosoma, in 
the Trypanosomatidae family and it is a member of the order Kinetoplastida.  It has a 
single flagellum that emerges from the posterior of the cell and which extends to the 
anterior attached to the membrane (Figure 1.3). The flagellum enables the organism to 
move which is essential for its survival  (Engstler et al., 2007). The flagullum is 
associated with the kinetoplast, a large organelle containing the DNA of the cell’s single 
mitochrondion. The flagellar pocket is the only site for endo- and exocytosis and is the 
site where receptors are located, such as the transferrin receptor (Steverding, 2006b).  
 
T. brucei has a complex lifecycle which is exclusively extracellular and alternates 
between the insect vector and the mammalian host (Figure 1.4).  Metacyclic 
trypanosomes are injected from the salivary gland of an infected tsetse fly into the 
mammalian host when it takes a blood meal. Trypanosomes multiply at the site of 
injection and then enter the blood and lymphatic system. The trypanosomes proliferate 
into the long, slender dividing form or the short, stumpy non-dividing form (Seed and 
Wenck, 2003, MacGregor et al., 2011). The latter is able to continue onto the next 
phase of the lifecycle, if taken up by a tsetse fly in a subsequent blood meal. In the 
tsetse fly the stumpy trypanosomes transform into procyclic trypamastigotes, which 
further develop into epimastigotes, then into metacyclic forms which migrate to the 
salivary gland of the tsetse fly, ready to be injected into another mammalian host 
(MacGregor et al., 2012).  
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1.2.1. Sub species  
T. b. brucei is morphologically indistinguishable from T. b. gambiense and T. b. 
rhodesiense.  T. b. brucei is susceptible to lysis in normal human serum due to innate 
trypanosome lytic factors, e.g. High Density Lipoproteins (HDLs), while T. b. 
gambiense and T. b. rhodesiense are resistant to HDLs and are able to persist in the 
blood and cause disease (De Greef et al., 1989, Vanhamme and Pays, 2004, Pays et al., 
2006). 
 
A proposed mechanism for how T. b. gambiense survives in normal human serum is due 
to expression reduction of haptoglobin receptor gene (Hp/Hb) leading to a reduced 
uptake of Trypanosome Lytic Factor-1 (TLF-1). The TLF-1 is found on has been shown 
to be taken up by the haptoglobin receptor and by reducing expression of this gene T. b. 
gambiense confers resistance to normal human sera (Kieft et al., 2010).  
 
T. b. rhodesiense has been shown to express the serum resistance-associated (SRA) 
gene which is the cause of the parasites resistance to normal human sera (De Greef and 
Hamers, 1994, Gibson, 2005). The SRA protein is similar to a truncated variant surface 
glycoprotein (VSG) and has been postulated to interact with apolipoprotein L1 that is 
associated with HDLs, preventing parasite cell lysis (De Greef and Hamers, 1994, 
Gibson, 2005, Pays et al., 2006). 
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1.2.2. Clinical presentation  
Symptoms alone are not sufficient to confirm diagnosis of HAT, therefore additional 
diagnostic testing is required, as some symptoms of HAT are similar to other diseases 
found in the same region, e.g. malaria or typhoid (Chappuis et al., 2005). In some cases, 
patients present with a chancre, a swelling and sometimes ring-like mark that is caused 
by localised inflammation at the site of inoculation (Sternberg, 2004). This is more 
common in T. b. rhodesiense infections and in non-Africans (Jelinek et al., 2002). 
Cervical lymph nodes can appear swollen in up to 50 % of cases when the host is 
infected and this is known as Winterbottoms sign (Chappuis et al., 2005).  Patients also 
present with symptoms, including; general malaise, anaemia, headache, pyrexia, weight 
loss and weakness.  In addition there may be neurological symptoms, including 
psychiatric, motor, sensory and sleep abnormalities (Sternberg, 2004). The swelling of 
the lymph nodes and other non-specific symptoms are not exclusive to HAT but may be 
due to other causes (Chappuis et al., 2005). However, the reversal of sleep-wake cycle 
is typical to HAT, with day time somnolence and nocturnal insomnia (Lundkvist et al., 
2004, Rodgers, 2010).   
 
1.2.3. Disease progression 
Trypanosomes are transmitted mostly via the bite from an infected tsetse fly but 
infections caused by blood exchange and congenital infections have been reported 
(Rocha et al., 2004, Welburn et al., 2009).   
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The trypanosomes progress from the site of infection through the blood and lymphatic 
system of the host known as the haemolymphatic stage or the first stage of the disease. 
Eventually the disease can progress, over a period of time ranging from a number of 
weeks to years, to the neurological stage, otherwise known as the second stage (Checchi 
et al., 2008). In T. b. rhodesiense infections the disease progresses from first to the 
second stage within three weeks to two months, and death occurs within six months in 
>80 % of cases, while T. b. gambiense infections can take up to many years to progress 
to the second stage (Odiit et al., 1997, Chappuis et al., 2005). However there is growing 
evidence of individuals that remain asymptomatic for years and others that can self-cure 
(Kaboré et al., 2011, Jamonneau et al., 2012, Sternberg and MacLean, 2010). 
 
The colonisation of the brain requires the trypanosomes to enter the hostile environment 
of the Cerebal Spinal Fluid (CSF) and the stroma of the choroid plexus (Wolburg et al., 
2012). In mice, trypanosomes localise near the gila limitans, where they can re-populate 
blood vessels and disrupt the sleep wake cycle (Wolburg et al., 2012). Typically, if no 
treatment is administered infected individuals die from severe wasting, dysfunctional 
immune system, deep coma and seizures. Often death is hastened by multiple other 
infections (Chappuis et al., 2005, Rodgers, 2010).   
 
1.2.4. T. brucei and the immune response 
Trypanosomes have the ability to evade the host’s adaptive immune system enabling 
them to live in the blood of patients. In the mammalian host the blood stream form 
trypanosomes are covered by a dense monolayer of identical glycoproteins called VSG 
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(Vickerman, 1978). The VSG coat protects the trypanosome plasma membrane from 
elements of the host’s innate immune system, e.g. complement (Ortiz-Ordonez et al., 
1994), and the hosts adaptive immune system, e.g. antibodies (Figure 1.5) (Schwede et 
al., 2011). There are over 1000 genes that encode for different, immunologically distinct 
VSG proteins that share similar tertiary protein structures (Weirather et al., 2012, 
Carrington and Boothroyd, 1996). Each VSG monomer is attached to a 
glycosylphosphatidylinositol (GPI) anchor which is then incorporated into the cell 
surface membrane as a homodimer (Ferguson et al., 1985, Ferguson et al., 1988, 
Schwartz and Bangs, 2007).  Periodically a different VSG clone will emerge (antigenic 
variation) leading to the evasion of a small number of trypanosomes from the host 
adaptive immune system these ‘switched’ parasite with the new VSG then dominate the 
trypanosome population (Oladiran and Belosevic, 2012, Gjini et al., 2010, Horn and 
McCulloch, 2010, Rudenko, 2011, Jackson et al., 2012).    
 
The host immune system responds to the trypanosome infection by producing a 
polyclonal expansion of B-cell lymphocytes (Magez et al., 2008, Tabel et al., 2008, 
Bockstal et al., 2011).  Immunoglobulin (Ig) G and IgM have been shown to bind to the 
VSG on the trypanosome cell surface where the bound IgG can be rapidly internalised 
without damage to the trypanosome (O'Beirne et al., 1998, Engstler et al., 2007). It has 
been proposed this adds to the parasite’s defence against the host immune system to 
ensure persistence and further transmission (MacGregor et al., 2011, Namangala, 2011, 
MacGregor et al., 2012).  It has been suggested that trypanosomes may play a role in 
modulating the host immune system (Vincendeau and Bouteille, 2006, Millar et al., 
1999, Gjini et al., 2010, Paulnock et al., 2010).   
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Disease severity has also been shown to have links between the parasite genotype and 
the host immune and inflammatory response (MacLean et al., 2004, MacLean et al., 
2006, MacLean et al., 2007) e.g. levels of interferon-γ (IFN-γ) and interleukin-10 (IL-
10), both pro and anti-inflammatory cytokines which confuse the host immune response 
(Courtin et al., 2007, Sternberg, 2004, Sternberg and MacLean, 2010, Bucheton et al., 
2011). On balance it appears to be a combination of parasite and host genetic factors 
that determine the virulence of HAT (Antoine-Moussiaux et al., 2009, Garcia et al., 
2006, Sternberg and MacLean, 2010). 
 
1.3. Diagnosis of HAT  
HAT diagnosis in the field faces many difficulties ranging from the medical to the 
logistical e.g. screening teams attending communities in remote rural locations, and 
during violent conflicts (Chappuis et al., 2005, Tong et al., 2011a, Van Nieuwenhove et 
al., 2001). Once they are with the communities, the screening teams must recruit the 
entire local population into the HAT screening programme, otherwise under-reporting 
and under-estimations of infection rates will occur (Mpanya et al., 2012, Mumba et al., 
2011, Odiit et al., 2005, Robays et al., 2004).  The identification of infected individuals 
relies principally on screening teams that visit at-risk communities or from patients 
seeking medical help (Odiit et al., 2004, Deborggraeve and Büscher, 2010). Some 
patients remain asymptomatic for years so early diagnosis of any infected individuals 
benefits not only the patient but also the community where these individuals  act as  
parasite reservoirs (Jamonneau et al., 2010).  
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In areas endemic for T. b. gambiense individuals are screened using the CATT (section 
1.3.1.1), should this test be positive with increasing blood dilutions (1:16), patients are 
further examined for the presence of trypanosomes. Samples of their blood and/or from 
their cervical lymph nodes are examined by microscopy. If parasites are found, the 
disease is staged. Staging requires sampling of the cerebral spinal fluid, where the 
probability of the parasites penetrating the brain is determined.  
 
In areas endemic for T. b. rhodesiense, analysis of body fluids by microscopy is the 
main diagnosis step, these fluids include, blood samples, lymph node and chancre (if 
present) aspirations. If trypanosomes are present the disease is staged as described 
above. In some areas T. b. rhodesiense and T. b. gambiense infections are in close 
geographical proximity (Picozzi et al., 2005) which raises concerns for future 
differential diagnosis for each sub-species, which at present can only be determined in a 
laboratory setting as there is not a field applicable test. 
 
1.3.1. Current diagnostic tools 
Diagnostic tools are required, particularly for T. b. gambiense infections due to the low 
density of parasites in the blood, which can be below the detection limits of microscopy 
(Wastling and Welburn, 2011).  Diagnostic tools include procedures to improve 
microscopy and serodiagnostic tests, the latter is defined as detecting either circulating 
parasite antigens or antibodies that recognise parasite antigens (Hutchinson et al., 
2004).  Here I shall discuss a selection of diagnostic tools and their relevance for the 
diagnosis of HAT in the field. 
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1.3.1.1. Card Agglutination Test for Trypanosomiasis (CATT) 
The current gold-standard field diagnostic tool for HAT screening for suspect T. b. 
gambiense cases is the CATT. It is a serological test which detects host antibodies in a 
suspension of fixed and stained T. b. gambiense trypanosomes expressing LiTaT1.3 
VSG (Magnus et al., 1978).  Over the years, the CATT screening tool has been 
optimised to improve stability, sensitivity (ranging from 87 % to 98 %) and specificity 
(95%) (Chappuis et al., 2005). Such modifications include dilution of the blood 
samples, the use of multiple trypanosome clones expressing different VSGs and 
improvements in thermostability (Jamonneau et al., 2000, Chappuis et al., 2004, Hasker 
et al., 2010, Truc et al., 2002b).   
 
Despite the usefulness and wide deployment of the CATT screening tool, it has several 
widely acknowledged limitations (Radwanska, 2010, Brun et al., 2010, Wastling and 
Welburn, 2011, Penchenier et al., 2003). These include varying degrees of sensitivity 
and specificity, which in part can be attributed to the agglutination test itself, which 
requires subjective judgements whether a patients sample contains antibodies or not 
(Figure 1.6). More profoundly, it has been identified in some places that the T. b. 
gambiense strain is not expressing the LiTAT1.3 VSG gene, and therefore patients do 
not generate detectable antibodies (Dukes et al., 1992). The CATT screening tool 
cannot be used to detect T. b. rhodesiense infections as T. b. gambiense specific strains 
in are used in this test and antibodies from T. b. rhodesiense infected patients do not 
cross-react (Fèvre et al., 2005). On the other hand, cured patients can have antibodies 
that can persist up to three years, leading to the possibility of false positive tests (Paquet 
et al., 1992), which is a weakness of any test that relies on antibody detection.  CATT 
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also requires trained screening personnel to use it and requires the need to cultivate 
infectious parasites for manufacture (Robays et al., 2004, Truc et al., 2002a).   
 
1.3.1.2. Loop-Mediated Isothermal amplification (LAMP) and Polymerase 
Chain Reaction (PCR) tools 
Further methods have been developed to detect parasites or parasite derived products 
overcoming the limitations of antibody serological diagnosis. The detection of parasite 
DNA in blood by loop-mediated isothermal amplification (LAMP) of DNA (Wastling et 
al., 2010) methods are under investigation and are summarised in a recent review 
(Mugasa et al., 2012).  While studies have been carried out to assess and validate the 
performance of LAMP in the ambient temperatures of tropical countries (Thekisoe et 
al., 2009), the diagnosis procedure still requires lab-based equipment and reagents, such 
as buffers and primers, similar to PCR amplification based diagnostic tools 
(Deborggraeve and Büscher, 2010, Becker et al., 2004, Mugasa et al., 2010). This 
platform is currently being investigated by the Foundation for Innovative New 
Diagnostics (FIND) which was commissioned by the World Health Organisation 
(WHO) to develop diagnostic tests for diseases of poverty, including HAT, tuberculosis 
and malaria (Wastling and Welburn, 2011).   
 
Despite the limitations of potential use as a field screening tool, the LAMP platform has 
been shown to detect down to 1 fg of trypanosome DNA, however this was achieved 
with purified DNA as the starting material (Thekisoe et al., 2007). 
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1.3.1.3. Microscopy 
Microscopy is used in the field to identify parasites in bodily fluids, for example, blood 
and CSF (Matovu et al., 2012). Microscopy is, at present, the ultimate proof that a 
patient is infected, however this technique lacks sensitivity and requires trained 
personnel and laboratory equipment. The lack of sensitivity is more relevant to T. b. 
gambiense infections where parasite density ranges from 10,000 to below 100 parasites 
per ml, the latter being below the threshold of microscopy (Brun et al., 2010).  
Examination of blood from a finger prick has a detection limit of 10,000 trypanosomes 
per ml (Büscher and lejon, 2004).  Developments to concentrate trypanosomes from 
infected blood and fluids, such as haematocrit centrifugation (HCT) and the mini anion 
exchange centrifugation technique (mAECT) have improved detection limits to less 
than 100 trypanosomes per ml (Biéler et al., 2012, Büscher et al., 2009, Camara et al., 
2010). However these methods still require lab based equipment and trained personnel.  
 
1.4. Staging the infection and treatments 
As described earlier in section 1.2.3 (disease progression), staging the infection is 
necessary to predict whether the trypanosomes have penetrated the brain (Kennedy, 
2008).  This will determine which drug the patient is treated with as some drugs are 
effective only in the first stage of the disease. Staging takes place by sampling the CSF 
by a lumbar puncture and counting the number trypanosome and/or lymphocyctes per µl 
and/or measuring the IgM concentration of the CSF (Chappuis et al., 2005). The 
classification/determination of second stage HAT is based on the number of the afore-
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mentioned measured properties which are set as guidelines in each country (Kennedy, 
2006b, Chappuis et al., 2005).   
 
Treatment is administered after the patient has been diagnosed and staged. Many of the 
drugs in current use have been reported to have severe limitations (Fairlamb, 2003). 
First stage T b. gambiense may be treated using Pentamidine and Suramin  but first 
stage T. b. rhodesiense is only responsive to Suramin (Bouteille et al., 2003). These 
drugs are reasonably well tolerated but side effects may be experienced e.g. liver and 
kidney damage (Welburn and Maudlin, 2012). These compounds do not penetrate the 
blood-brain barrier therefore different second stage drugs are required. Treatment of 
second stage T. b. gambiense is mainly by Nifurtimox-Eflornithine combination therapy 
(NECT) and Melarsoprol is now only used for T. b. rhodesiense (Priotto et al., 2009, 
Opigo and Woodrow, 2009, Kennedy, 2012).  Reactive encephalopathy occurs in 5-
10% of patients treated with Melarsoprol and approximately half of those cases die 
(Kennedy, 2006a, Fairlamb, 2003). Clearly new, safe, affordable treatments that are 
effective in both stages and against both sub-species of trypanosomes are urgently 
needed.  
 
1.5. Lateral flow tests  
Lateral flow devices are simple tests that can rapidly detect nanogram amounts of 
antibodies or antigens in finger-prick blood samples without the need for any ancillary 
equipment (Posthuma-Trumpie et al., 2009, Bandla et al., 2011).  Lateral flow tests 
have been adopted for diagnosis use in other diseases such as malaria, Leishmaniasis 
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and Theileria annulata infections (Bell and Perkins, 2008, Abdo et al., 2010, El-
Moamly et al., 2011). These lateral flow tests (point of care tests) are relatively stable at 
ambient temperatures and require limited training for use (Robert, 1997, Posthuma-
Trumpie et al., 2009).  The premise for most of these tests is a known diagnostic protein 
candidate(s), these are usually recombinant proteins if the availability of native 
diagnostic antigens is too challenging. The candidate antigens are assessed and 
validated, usually by enzyme linked immunosorbent assay (ELISA), leading to the 
adaptation and production of lateral flow assays. 
 
Due to the very low parasitemia levels in patients infected with T. b. gambiense, a 
lateral flow test that detects host antibodies (rather than parasite antigens) was 
considered more likely to have the necessary sensitivity and specificity.  
 
1.6. Summary  
There have been many calls for new diagnostic tools and treatments to be designed and 
made available, due to the severe limitations of the current tools (Brun and Blum, 2012, 
Welburn et al., 2009). In particular a new test should have greater specificity to avoid 
false positive results (Radwanska, 2010).   Recently the FIND has invested in 
developing new diagnostic tests for HAT (Steverding, 2006a). Their emphasis is on 
‘piggy-backing’ on diagnostic platforms such as LAMP although they are investigating 
other platforms (Ndung'u et al., 2010, Matovu et al., 2012). However, these diagnostic 
methods require relatively sophisticated laboratory equipment (Robert, 1997).  
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In summary, there is well accepted case for developing a simple, low-cost diagnostic 
device with greater sensitivity and specificity than the current field tests (Matovu et al., 
2012, Simarro et al., 2011).  With this aim in mind, we set out to identify novel 
diagnostic antigens for our prototype lateral flow test device. We chose to use a non-
biased (proteomics) approach to potential biomarkers rather than the candidate antigen 
approach used in previous tests.  
 
We are extremely grateful to Professor Philippe Büscher (Institute of Tropical 
Medicine, Antwerp) for sending us the initial human serum samples, without which 
none of this work would have been possible. We are also extremely grateful to the 
WHO and the HAT specimen bank, firstly for granting us use of these very precious 
human serum samples but also for all their assistance, in particular for sending clinical 
details of the patients sampled.  The lateral flow assays would not have been created 
without the help of Dr. Steven Wall and Richard Lamotte (British Biocell International, 
Dundee), to whom we are extremely grateful. 
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2. Aims  
2.1. The overall aim of this project was to develop a field compatible lateral flow 
diagnostic test for human African Trypanosomiasis.  
 
The specific aims were: 
• To discover potential diagnostic antigens for HAT. 
• To recombinantly express and purify a selection of antigens. 
• To assess and validate recombinant, synthetic or native antigens for diagnostic 
potential with clinically assessed infection and control human serum samples. 
• To develop the most promising candidate antigen(s) into lateral flow format for 
screening and assessment with human sera. 
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3. Materials and Methods 
3.1. Reagents 
3.1.1. Chemicals and reagents 
All general chemicals were purchased from Sigma (St Louis, USA) or VWR (Leven, 
Belgium) unless otherwise stated. All media for E. coli cell cultures, including 
antibiotics solutions, were made and supplied by the Media Kitchen service in the 
College of Life Sciences, University of Dundee.  Phosphate Buffered Saline (PBS) was 
supplied by the Media Kitchen service as a ten times concentrated solution. 
 
3.1.2. Serum samples 
Two sets of samples were used the first, (Identification sera set) were kindly provided 
by Philippe Büscher (Institute of Tropical Medicine, Antwerp) and consisted of nine 
sera from T. b. gambiense infected patients and nine from matched non-infected patients 
(0.5 ml to 1 ml aliquots). The second (Validation sera set) were sera from 145 patients 
(200 µl aliquots) and were obtained from the WHO Human African Trypanosomiasis 
specimen Bio-Bank. Serum samples were aliquoted and stored at either -80 oC for long-
term storage or in 50 % (w/v) glycerol at -20 oC when prepared for ELISA analysis. 
Freeze-thawing was kept to a minimum; samples from P. Büscher and WHO were 
freeze-thawed three times and twice, respectively, prior to use in ELISA tests. 
 
3.1.2.1. Human serum samples ethics 
Ethical approval was in place for all serum samples used in this study, whereby the 
samples were taken with the informed consent of the patient. The WHO HAT specimen 
Bio-Bank samples ethnics included the purpose of distribution of serum samples for the 
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purpose of developing diagnostic tests. The local ethics board (NHS Tayside) also 
reviewed and approved the study retrospectively.  
  
3.2. Trypanosome preparations 
3.2.1. Ethics 
The animal procedures were carried out according the United Kingdom Animals 
(Scientific Procedures) Act 1986 and according to specific protocols approved by The 
University of Dundee Ethics Committee and as defined and approved in the UK Home 
Office Project License PPL 60/3836 held by MAJF. 
 
3.2.2. Preparations of T. b. brucei lysate  
Six BalbC mice were injected with between 105 and 106 T. b. brucei strain 427 variant 
MITat 1.4 cells.  After three days, infected mouse blood was harvested with sodium 
citrate anticoagulant, adjusted to 107 parasites per ml with phosphate buffer saline 
(PBS) (2.7 mM KCl, 1.5 mM KH2PO4, 136.9 mM NaCl, 8.9 mM NA2HPO4●7H2O, pH 
7.4) and aliquots of 0.5 ml were injected into the peritoneal cavity of 12 Wistar rats. The 
rat blood was harvested after 3 days with citrate anticoagulant and centrifuged at 1000 x 
g for 10 min at 4 oC (4K15 Sigma Centrifuge). Plasma was removed and the buffy coat 
which contained the trypanosomes was resuspended in separation buffer plus glucose  
(SB + glucose; 57 mM Na2HPO4, 3 mM KH2PO4, 44 mM NaCl, pH 8, 10 g/l glucose) 
and applied to a DE52 DEAE-cellulose (Whatman, GE Healthcare, Maidstone, 
England) column that had been pre-equilibrated with SB + glucose. The trypanosomes 
were washed through the column with SB + 1 % (w/v) glucose, counted, centrifuged 
(900 g, 15 min, 4 oC), resuspended in 1 ml PBS and then adjusted to 1x109 parasites/ml 
in ice-cold lysis buffer (50 mM Na2PO4, pH 7.2, 2 % (w/v) n-octyl β-ᴅ-glucopyranoside 
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(nOG) detergent, 1 mM phenylmethsulfonyl fluoride (PMSF), 1 mM tosyl-L-lysine 
chloromethyl ketone (TLCK), 1 µg/ml aprotinin, 1 µg/ml leupeptin and 1 x Roche 
protease inhibitor cocktail minus ethylenediamine tetraacetic acid (EDTA) (Mannheim, 
Germany). The lysate was incubated for 30 min on ice and then centrifuged at 100,000 
g for 1 h at 4oC (Beckman Ultracentrifuge, 50.2 Ti rotor).  
 
3.2.3. Preparation of soluble Variant Surface Glycoprotein from T. b. brucei 
lysate 
The sVSG purification method is a well-established protocol that has been used in the 
lab and is described in Mehlert et al, 2002.  The sVSGs were further purified by gel 
filtration using a Sephacryl S200 column (4x90 cm) equilibrated with 0.1 M NH4HCO3. 
The samples were run on an SDS PAGE gel to check for purity and were considered 
>95 % pure (data not shown). The sVSGs were kindly purified and prepared by Angela 
Mehlert. 
 
3.3. Molecular methods for identification of antigens 
3.3.1. Virus deactivation of sera 
The samples provided by Professor P. Büscher underwent virus inactivation using a 
modified procedure that retains antibody reactivity (Burnouf et al., 2006). Briefly, 1 % 
(w/v) Tri(n-butyl)phosphate (TnBP) (Fluka, UK) and 1 % Triton X-45 (w/v) (Tx-45) 
(Sigma, USA) were each added to a final concentration of 1 % to thawed serum 
samples.  The sera were vortexed for 2 min and were incubation in a waterbath at 31 oC 
for 4 h.  The sera were inverted every half hour.   To extract the TnBP and TX-45, 2 ml 
of sterile castor oil (Riedel-de Haën, Germany) was added to each serum sample, 
inverted and centrifuged at 3800 x g for 30 min (4K15 Sigma Centrifuge). TnBP and 
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TX-45 partitions in the oil layer.  The oil-extraction was repeated three times and the 
virus-inactivated sera (lower phases) were aliquoted and stored at -80 oC.  
 
3.3.2. IgG purification from serum 
Following virus deactivation, 125 µl of sera from four infected and four uninfected 
(control) patients were pooled. Each pool was applied to a 1 ml protein G column (GE 
Healthcare, Sweden) equilibrated in PBS (Table 3.1). The columns were washed with 
10 ml of PBS and the bound IgG antibodies were eluted with 50 mM sodium citrate pH 
2.8, and collected in 1 ml fractions into tubes containing 200 µl of 1 M Tris-HCl, buffer 
pH 8.5, to immediately neutralise the pH.  Peak fractions containing IgG were 
combined and dialysed for 16 h against coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, 
pH 8.3). 
 
3.3.3. Protein concentration determination  
Aliquots of protein solutions were transferred directly, or diluted then transferred, to 
cuvettes (Eppendorf) and the absorbance at 280 nm was measured on Eppendorf 
BioPhotometer. Cuvettes containing only the buffered solutions were used as blanks.   
 
3.3.4. Coupling of IgG to cyanogen bromide-activated (CNBr) Sepharose beadsTM  
CNBr-activated SepharoseTM beads (Sigma, Sweden) were weighed to give a gel 
volume of 0.5 ml or 0.75 ml, for first immunoprecipitation and 2nd immunoprecipitation 
respectively. The beads were hydrated in 1 mM HCl then equilibrated in coupling 
buffer (0.1 M NaHCO3, 0.5 M NaCl, pH 8.3).  The beads were mixed with purified 
infection IgG or purified control IgG (4 mg of each for the 1st immunoprecipitation and 
7.2 mg for the 2nd immunoprecipitation) in a final volume of 3 ml coupling buffer for 16 
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h at 4 oC.  The coupling of IgG to the gel was confirmed by measuring the absorbance 
of the supernatant at 280 nm (A280 < 0.05) (10 min, 4oC, 500xg in 4K15 Sigma 
Centrifuge). The SepharoseTM-IgG conjugates were centrifuged at 500 x g (10 min, 4 
oC, 4K15 Sigma Centrifuge) and the beads were resuspended in 15 ml 1 M 
ethanoamine, pH 9, for 2 h at room temperature. Following this, the IgG-SepharoseTM 
beads were washed with three cycles of 0.1 M Tris-HCl, pH 8.0, 0.5 M NaCl followed 
by 0.1 M sodium acetate buffer, pH 6.0, 0.5 M NaCl and finally washed and stored in 
PBS containing 0.05% (v/v) NaN3.  
 
In the first immunoprecipitation experiment, two further control resins were also 
prepared following the same procedure as above.  These were ‘Non-matched control’ 
IgG from purified IgG from serum originated from a person that has never been exposed 
to Trypanosomes.  ‘Beads only’ are beads that have no IgG, this was to address whether 
CNBr-activated SepharoseTM beads could bind to trypanosome derived products.  
 
3.3.5. Immunoprecipitation  
For the 1st immunoprecipitation experiment, aliquots of T. b. brucei lysate (1010 cell 
equivalents) were incubated with the SepharoseTM-IgG (infection and non-
infection/control) gels, rotating for 1 h at 4 oC. The SepharoseTM-IgG were centrifuged 
10 min at 4 oC, 600 x g (4K15 Sigma Centrifuge) and the supernatent cell lysate were 
removed. The gels were washed with 14 ml 50 mM Na2PO4 pH 7.2, 2 % (w/v) nOG, 0.5 
M NaCl for 10 min at 4 oC then centrifuged at 600 x g, for 10 min at 4 oC. This wash 
step was repeated three times. The gels were washed with 14 ml 10 mM Na2PO4, pH 
7.2, 1 % (w/v)  nOG for 10 min at 4 oC then centrifuged at 600 x g, for 10 min at 4 oC. 
This second wash step was repeated three times. Trypanosome proteins that bound to 
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the SepharoseTM-IgG were eluted with three 500 µl elutions of 50 mM Sodium Citrate 
pH 2.8, 1% (w/v) nOG, collected in tubes containing 110 µl 1 M Tris pH 8.5.  The three 
elutions were combined and freeze-dried (machine). The lyophilised sample was 
resuspended in 200 µ MilliQ H2O plus 1 ml ice cold 100 % Ethanol and stored at –20 
oC for 16 h. The ethanol precipitation was centrifuge at 16,000 x g for 15 min at 4 oC 
(5415 R Eppendorf Centrifuge). The pellet was washed with 500 µl cold MilliQ H2O 
and centrifuged at 16,000 x g for 10 min at 4 oC (5415 R Eppendorf Centrifuge). This 
was repeated twice. The pellet was then resuspended in 30 µl Sodium dodecyl sulphate 
(SDS) Sample buffer (SB)  (Invitrogen, Carlsband, CA, USA) containing 100 mM 
dithiothreitol (DTT) (Formedium, England). The samples incubated at 100 oC for 7 min 
and then sent to the proteomics facility for tryptic digestion and protein identification.  
 
In the 2nd immunoprecipitation experiment, aliquots of T. b. brucei lysate (1010 cell 
equivalents) were incubated with the SepharoseTM-IgG (infection and non-
infection/control) gels, rotating for 3 h at 4 oC. The gels were then packed into 
disposable 10 ml columns and washed with 10 ml of 10 mM Na2PO4, pH 7.2, 200 mM 
NaCl, 1 % (w/v) nOG, followed by 10 ml of 5 mM Na2PO4 pH 7.2, 1 % (w/v) nOG. The 
trypanosome proteins bound to the SepharoseTM-IgG gels were eluted three times with 
750 µl of 250 mM sodium citrate, pH 2.8, 1% (w/v) nOG and the eluates were pooled 
and neutralised with 1.5 M Tris-HCl, pH 9 and further concentrated to 140 µl using a 
centrifugal concentrator (Millipore, 0.5 ml capacity with 3 kDa MW cut off membrane 
(Bedford, MA, USA)). To remove eluted IgG, this fraction was mixed with 60 µl PBS-
equilibrated Protein G agarose beads (Pierce, Rockford, USA) which were incubated for 
10 min and removed by centrifugation (600 x g, 10 min, in a 5415 R Eppendorf 
Centrifuge). The supernatant which contained the trypanosome proteins, were then 
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transferred to low binding Eppendorf tubes and the proteins were precipitated by adding 
1 ml ice-cold ethanol and incubated for 34 h at -20 oC. The ethanol precipitation was 
followed by centrifuge at 16,000 x g for 15 min at 4 oC (5415 R Eppendorf Centrifuge). 
The pellet was washed with 500 µl cold MilliQ H2O and centrifuged at 16,000 x g for 
10 min at 4oC (5415 R Eppendorf Centrifuge). This wash step was repeated twice. The 
pellet was then resuspended in 30 µl SDS SB (Invitrogen, Carlsbad, CA, USA) 
containing 100 mM DTT. The samples incubated at 100 oC for 7 min and then sent to 
the proteomics facility as before.  
 
In both immunoprecipitation experiments, 10 % of the resuspended protein in SDS SB 
elutions were loaded on a SDS polyacrylamide gel electrophoresis (PAGE) gel 
(Invitrogen, Carlsbad, CA, USA) and silver stained to estimate protein concentration 
and how much to load for the SDS PAGE gel run by the proteomics facility (see Section 
3.5 (Silver stain) and Section 3.4 (Proteomics)). 
 
3.3.6. SDS PAGE  
Samples were run on pre-cast Novex 4-12 % Bis-Tris SDS-PAGE gels with MOPS 
running buffer system (Invitrogen) in a XCELL-II mini-tank (Novex) at 200 V using a 
BioRad Power Pac Junior.  SDS-PAGE gels were also cast by hand for methods that did 
not require downstream proteomics analysis, using the recipe in Table 3.2. The 
assembled gels were run in a Tris-Glycine buffer (25 mM Tris base, 250 mM glycine, 
0.1 % (v/v) SDS) in a MiniPROTEAN Tetra cell (BioRad) at 180 V using a Power Pac 
300 (BioRad). Samples were prepared with 4x SDS Sample Buffer (Invitrogen) and 
DTT (0.1 M) as a reducing agent.  Before loading samples were placed in a heating 
block set at 100 oC for 5 to 10 min.  
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Table 3.2: SDS-PAGE recipe for hand cast gels. 
 Stacking gel Resolving gel 
10 % 12 % 
30 % Bis-acrylamide 
(BioRad) 
0.4 ml 1.67 ml 2 ml 
1 M TrisHCl pH 8.8 - 1.2 ml 1.2 ml 
1.5 M TrisHCl pH 6.8 0.6 ml - - 
10 % (v/v) SDS 25 µ 50 µl 50 µl 
Water 1.4 ml 2.1 ml 1.7 ml 
10 % (v/v) APS (VWR) 35 µ 70 µl 70 µl 
TEMED (VWR) 3.4 µ 7 µl 7 µl 
  
3.3.7. Coomassie and Silver staining  
Proteins on the SDS PAGE gels were subsequently stained with 0.1 % Coomassie 
brilliant blue stain in 40 % methanol, 10 % acetic acid for 1 h. The excess stain was 
removed and gels are washed with 40 % methanol, 10 % acetic acid (Destain solution) 
or with 10 % acetic acid only. For protein mass fingerprinting, the gel was stained for 
30 min with SimplyBlueTM Safe Stain (Invitrogen, Carlsbad, CA, USA) and destained 
with water. When protein quantities were too low to be detected by Coomassie staining, 
gels were stained with silver using the SilverQuest TM kit (Invitrogen) following the 
manufacturer’s instructions.  
  
3.4. Proteomic analysis 
Following ethanol precipitation, the proteins eluted from the infection IgG and control 
IgG gels were dissolved in SDS sample buffer, reduced with 100 mM DTT and run on a 
precast 4-12% BisTris gradient SDS-PAGE gel (Invitrogen) using the MES running 
system. All mass spectrometry was carried out by the proteomics facility (University of 
Dundee). The gels were stained with colloidal Coomassie blue and equivalent regions of 
the infection and control lanes were cut out and underwent in-gel alkylation with 
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iodoacetamide and were digested with trypsin. The tryptic peptides were analysed by 
liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) on a 
Thermo Orbitrap XL system. 
 
3.4.1. MASCOT Software 
MASCOT daemon software was used to match peptides to the predicted trypanosome 
protein databases (combined GeneDB and UniProt predicted protein sequences). 
 
3.5. Molecular Biology Protocols 
3.5.1. In silico analyses and searches of DNA and protein sequences 
The identified protein sequences were used to BLASTp search the T. b. brucei predicted 
protein database (from the GeneDB database, http://www.genedb.org) (Logan-Klumpler 
et al., 2012).  Protein sequence multiple alignments were assembled using 
CLUSTALW2 (Larkin et al., 2007) and Jalview (Waterhouse et al., 2009).  In silico 
plasmid construction were assembled using GCK (Texcto BioSoftware) or CLC Main 
Workbench (CLC Bio). Protein extinction coefficients for each recombinant protein 
were calculated by ProtParam (Gasteiger et al., 2005). Recombinant constructs were 
designed using predictors for signal peptide, SignalP (Petersen et al., 2011) for 
transmembrane domains using TMpred (Hofmann and Stoffel. 1993).  When construct 
design required smaller domains to be cloned out of a larger domain, GLOBplot was 
consulted to identify protein sequences with high degrees of disorder, which may to be 
joining domains together (Linding et al., 2003).  Rare codon predictions were calculated 
using Prof. Charles Bond’s rare codon predictor (University of Melbourne, Australia), 
which recommended that all recombinant proteins be expressed in E. coli cell lines that 
contained additional rare codon tRNA plasmids.  
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3.5.2. Primers 
Primers used are listed in Table 3.3. Where possible primers were designed to have a 
similar melting point (Tm) of 60 oC and to contain ~20 bp of complementary sequence. 
The Tm was calculated according to the following formula: Tm = (G+C)x 4 oC + (A+T)x 
2oC. Only nucleotides in the complementary sequence of the primer were included in 
the calculations.  
 
Table 3.3: List of primers 
Name Sequence Tm 
(oC) 
Restriction 
sites 
F-GRESAG4-MG-46-
Nco1 
CATGCCATGGGCTACAGTGGCAAGATTTC
AGCA 
60 Nco1 
R-GRESAG4-836-
Xho1 
CCGCTCGAGATTTATTAGTCGAATCCATTT
TGCTT 
60 Xho1 
F-GRESAG4-
KTIITGTN 
AGACAATAATAACAGGGACTAAT 60 For 
sequencing R-GRESAG4-
TPSLHIV 
TTGGTGACAGGTGAATCACAT 60 
F-GRESAG4-50-Nde1 TAATTACATATGATTTCAGCAAAGGTATA
TGATCCTATTACTGCA 
58 Nde1 
R-GRESAG4-840-
Xho1 
TTATATTAACTCGAGTAAAGCCAGCTGCC
ACAGCACCAATATGCT 
63 Xho1 
F-GRESAG4-46-Nde1 ATAATATCATATGTACAGTGGCAAGATTT
CAGCAA 
60 Nde1 
R-GRESAG4-407-
Xho1 
TATTATACTCGAGTAATTGGCACTCACCA
CCAAAGT 
60 Xho1 
R-GRESAG4-401-
Xho1 
TAATTACTCGAGTTAGTCACCAACCACAA
GATCATCAATTACATAAC 
59 Xho1 
F-GRESAG4-401+-
Nde1 
TAATATATTCATATGGACTTTGGTGGTGA
GTGCCAAGGCAT 
61 Nde1 
F-ISG64-24-Xho1 TATAATTACTCGAGAATGCAAAGTTGACC
AAAGATGGTGCGTT 
59 Xho1 
R-ISG64-363-BamH1 TATAATAGGATCCTTAATCACTAGTCTCCA
GGAGGTCACCGAA 
61 BamH1 
F-ISG75-30-HindIII-M TAATAATGAAGCTTCTATGAACTTACCTGT
CGCATATAAGCAGTATG 
57 HindIII 
R-ISG75-295-BamH1 TAATTAGGATCCTTATTCCAGATA 
CTGTGCAAGAGACTCCCTT 
60 BamH1 
F-ISG75-pL2-30-
BamH1-M 
TATAATGGATCCATGAACTTACCTGTCGC
ATATAAGCAGTATG 
57 BamH1 
R-ISG75-pL2-295-
Not1 
TTAAATGCGGCCGCTTATTCCAGATACTGT
GCAAGAGACTCCCTT 
60 Not1 
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All primers were synthesized by the Oligonucleotide Synthesis Service in the University 
of Dundee (http://www.lifesci.dundee.ac.uk/services/oligo/index.php). 
 
3.5.3. Plasmid vectors 
Plasmids used in this project include sub-cloning plasmids and plasmids used with 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible expression for recombinant 
protein purification.  
 
Table 3.4: Plasmid description 
Plasmid Purpose Source 
pCR2.1 Sub-cloning from PCR product for DNA 
sequencing 
(TOPO vectors) 
Invitrogen 
pET15b-
TEV 
E. coli overexpression plasmid containing N-
terminal His tag, with a modified multiple 
cloning site and TEV protease cleavage site. 
Kind gift from Dr. Scott 
Cameron (AHF group, 
University of Dundee) 
pGEX-TEV E. coli overexpression plasmid containing an 
N-terminal GST tag and a modified multiple 
cloning site (to the same as pET15b-TEV) 
and a TEV protease cleavage site.  
Kind gift from Jennifer 
Fleming (WNH group, 
University of Dundee) 
 
3.5.4. PCR 
All polymerase chain reactions (PCRs) were performed with High Fidelity Platinum(R) 
Taq DNA polymerase (Invitrogen, USA) in a 50 µl volume using a PTC-225 Peltier 
Thermal Cycler (MJ Research).  Conditions and programs are in Table 3.5.  PCR 
products were analysed by agarose gel electrophoresis. 
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Table 3.5: PCR reaction conditions 
Amplification Reaction 
conditions 
Primers Template DNA 
 
Genomic DNA        Plasmid 
GRESAG4, 
ISG64, ISG75 
1x High Fidelity 
PCR buffer 
0.2 µM 150 pg 50 pg 
2 mM Mg2SO4 
0.2 mM dNTPs 
1 U Platinum Taq 
 
Table 3.6: Amplification program 
Cycle Temperature (oC) Time 
1 94 2 min 
2-34 94 30 s 
55-65 (gradient on plate) 30 s 
72 1 min 30 
35 72 10 
 4 1 h 
   
3.5.5. Agarose gel electrophoresis 
For DNA separation, 1 % (w/v) agarose gels in 1x TAE (40 mM Tris-acetate, 1 mM 
EDTA) buffer containing 0.4 µg/ml ethidium bromide were used. The gels were run at 
80 V using BioRad Mini-Sub Cell GT tanks connected to Power Pac 300 power packs. 
All DNA samples were run in presence of 1x Blue/Organge Load dye (Promega, 
Madison, USA) and 1 Kb or 100 bp DNA ladders (Promega, Madison, USA) which 
were used to estimate DNA fragment size. The gels were imaged using a GelVue UV 
Transilluminator with a UGenius gel documentation system (Syngene).  
 
3.5.6. Gel extraction of DNA  
PCR derived DNA fragments of plasmid DNA were purified post separation by agarose 
gel by using the QIAquick® Gel Extraction Kit (Qiagen, Hilden, Germany). This was 
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followed by the microcentrifuge protocol and the DNA concentration was estimated by 
A260 in a spectrophotometer (Bio Photometer, Eppendorf) using UVettes (Eppendorf) 
with a 1 cm path length.  
 
3.5.7. Restriction endonuclease digestion 
Endonucleases were purchased from Promega (Madison, USA) or New England 
Biolabs (NEB, USA).  DNA to be digested was incubated with the restriction enzyme 
and the required digestion buffer at the recommended optimal temperature (usually 37 
oC) for 1 to 2 hours (Table 3.3). Small aliquots of the DNA were analytically (included 
only one enzyme digestion) were digested in parallel with the preparative digestion 
(usually included both restriction enzymes).  The digestion mix from the negative 
control, analytical digestions and the preparation were analysed by agarose gel 
electrophoresis.  
 
3.5.8. E. coli strains and cultures 
E. coli cells used for transformations post ligations were the high-efficiency TOP10 
cells (Invitrogen, USA) while DH5α (DSTT, Dundee) strain was used for plasmid 
propagation and sub-cloning. These cells were grown in Luria Broth (LB) medium 
(Table 3.7) containing 50 µg/ml ampicillin at 37 oC, 200 RPM in Infors HT incubators.  
As described earlier, in in silico predictions (Section 3.5.1), of tRNA codon bias 
occurred in all of the trypanosome sequences selected, overexpression cell line BL21 
CodonPlus (DE3)RIPL (Stratagene) was used as it compensated by containing plasmids 
for rare tRNA codons, encoding for Arginine, Isoleucine, Proline and Leucine. For 
overexpression of recombinant proteins cells were grown in 2x Tryptone Yeast extract 
(TY) medium (Table 3.7).  For bacterial stabilates, 100 µl of 80 % (w/v) glycerol 
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(AnalaR, VWR, France) were added to 800 µl of cells grown from a single colony in for 
16 h at 37 oC, 200 RPM and snap-frozen on dry-ice for storage at -80 oC.  
 
Table 3.7:  Media 
Medium Chemical substance Amount per 1 L (g) 
LB  
(Adjusted to pH 7) 
NaCl 10 
Tryptone 10 
Yeast extract 5 
2x TY 
(Adjusted to pH 7) 
NaCl 5 
Tryptone 16 
Yeast extract 10 
 
3.5.9. Ligation 
Concentrations of purified inserts and digested plasmid vectors were estimated by 
spectrophotometer (A260). A range of different ratios of vector to insert were used, 
including 1:1, 1:3 and 1:9 (vector:insert), also vector only controls were performed in 
parallel. The ligation reactions were set up to a 10 µl final volume using the Rapid DNA 
ligation kit (Roche, Mannheim, Germany) (Table 3.8).  
 
Table 3.8: Ligation reaction for expression plasmids (Roche) 
Reaction 
component 
Volume or amount 
Insert Ratios as above 
Vector Ratios as above 
5 x buffer 1.10 µl 
2x buffer 6 µl 
T4 ligase 0.5 µl 
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Table 3.9: TOPO-TA ligation 
Reaction component Volume or amount 
PCR product 4 µl  
TOPO-TA vector 1 µl 
Salt solution 1 µl 
 
The reaction mixture was incubated at room temperature for 20 min, 3.5 µl of each 
ligation was transformed into TOP10 competent cells (Invitrogen, USA).   
 
3.5.10. Transformation 
Aliquots of chemically competent cells (50 µl) were incubated with ~10 ng of plasmid 
DNA or 1/3 of a ligation mixture on ice for 5 min. Once cells were fully defrosted cells 
were heat shocked at 42 oC for 20 to 35 s depending on the strain of cells, and then were 
cooled on ice for 2 min. SOC medium was added to the cells, which were then grown at 
37 oC for 45 min at 200 RPM (Infors HT incubator) before being plated on LB + agar 
plates containing ampicillin and other antibiotics if required. 
 
3.5.11. Purification of plasmid DNA 
Plasmid DNA from transformed DH5α or TOP10 E. coli strains were derived from 
purified and prepared 5 ml cell cultures (minipreps) grown at 37 oC, 200 RPM for 16 h 
using the QIAprep® Spin Miniprep Kit (Qiagen, Hilden, Germany).   
 
3.5.12. DNA sequencing 
DNA sequencing was performed by the Sequencing Service at the University of 
Dundee, using the Applied Biosystems 3370 DNA analyzers. Regions of interested 
were sequenced twice in each direction, with the consensus sequence built in CLC Main 
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Workbench (CLCbio). Comparison between the consensus and the in silico sequences 
were performed using CLC Main Workbench and ClustalW2 (Larkin et al., 2007). 
 
3.6. Protein biochemistry for recombinant antigens 
3.6.1. Cell density measurement 
Cell density was monitored by measuring the density by Absorbance at 600 nm 
BioPhotometer (Eppendorf). 
 
3.6.2. Protein expression optimisation strategy 
A single colony was picked from a freshly transformed cell line, grown overnight on LB 
with antibiotics (AMP and CML), into 50 ml 2xTY media. Cultures were incubated at 
37 oC until the Absorbance at 600 nm (Abs 600) reached 0.3 or 0.8 and induce 
expression with IPTG (Formedium, England) 
 
Table 3.10. Optimisation of expression conditions: 
Condition IPTG Induction 
(Abs600) 
Length of 
induction (h) 
Temperature of 
Induction (oC) 
A 0.3 3 37 
B 0.8 3 37 
C 0.8 16 18 
 
Table 3.10: Optimisation of expression conditions, description: 
The first condition (A) is where the culture was induced with 1 mM IPTG at 
Abs600 at 0.3 and was expressed at 37 oC for 3 h.  
The second condition (B) is where the culture is induced at Abs600 of 0.8 and 
expression temperature was 37 oC for 3 h.  
Finally the third condition (C) uses the Abs 600 at 0.8 where the culture is cooled 
before being induced for 16 h at 18 oC.   
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3.6.3. Sample resuspension for SDS PAGE loading 
1 ml Uninduced and Induced samples were collected, the cell density was measured at 
Abs600 and the sample was centrifuged in a microcentrfuge (Eppendorf) for 17 seconds 
to pellet the cells. The supernatant was removed and the cell pellet was resuspended in 
corresponding volumes from the pre-made stocks (Table 3.11). Samples were boiled for 
5 to 10 min in a heating block and loaded on an SDS PAGE gel or frozen for use in 
other SDS PAGE gels.  
 
Table 3.11: Suspension of 1 ml cell culture pellet for relative loading for SDS 
PAGE gels.  
 
OD 1 M DTT 
(µl) 
4 x SDS SB 
(µl) 
mq H2O 
(µl) 
total (µl) 
0.3 6 15 24 60 
0.4 8 20 32 80 
0.5 10 25 40 100 
0.6 12 30 48 120 
0.7 14 35 56 140 
0.8 16 40 64 160 
0.9 18 45 72 180 
1 20 50 80 200 
1.1 22 55 88 220 
1.2 24 60 96 240 
1.3 26 65 104 260 
1.4 28 70 112 280 
1.5 30 75 120 300 
1.6 32 80 128 320 
1.7 34 85 136 340 
1.8 36 90 144 360 
1.9 38 95 152 380 
2 40 100 160 400 
2.2 44 110 286 440 
2.4 48 120 312 480 
2.6 52 130 338 520 
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2.8 56 140 364 560 
3 60 150 390 600 
3.2 64 160 416 640 
3.4 68 170 442 680 
3.6 72 180 468 720 
3.8 76 190 494 760 
 
3.6.4. Large scale over-expression and purification of recombinant proteins from 
E. coli 
Typically, cells containing the desired expression plasmid were selected for by streaking 
the stabilate cells or by re-transformation on LB containing amplicillin and 
chloramphenicol plates. Each selected colony was grown in 5 ml 2 x TY media, 37 oC, 
200 RPM (Thermos shakers), containing ampicillin and chloramphenicol, until cloudy. 
Each culture was inoculated into 0.5 L 2 xTY (with antibiotics) (in a 2L conical flask) 
and incubated at 37 oC, 200 RPM, until the cell density has reached desired Abs600.  At 
this point 5 ml 2 % (v/v) IPTG was added to the media to induce expression of the 
recombinant sequence. Induction continues for the appropriate duration and temperature 
as described in Table 3.10.  Cells were harvested by centrifugation (J6-MC Beckmann 
Centrifuge) at 4200 x g, 20 min at 4 oC. The supernatent was removed and the cell pellet 
is resuspended in buffer A (Table 3.x) (without protease inhibitors). The resuspension 
was either stored at -80 oC or processed immediately, see below. 
 
Table 3.12: Buffers used in Ni NTA purification 
Buffer Chemical Concentration 
Buffer A NaH2PO4  pH8 with NaOH 50 mM 
NaCl 300 mM 
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Lysis buffer (buffer A +) Imidazole 10 mM 
Wash buffer (buffer A+) Imidazole 20 mM 
Elution buffer (buffer A+) Imidazole 250 mM 
 
3.6.4.1. Cell lysis 
A Roche protease inhibitor cocktail tablet was added to lysis buffer/cell suspension. The 
cells were lysed by French Press above 10,000 psi. The cell lysate was clarified by 
centrifugation at 12,600 x g, 15 min, 4 oC (J2-21 Beckmann centrifuge).   
 
3.6.4.2. Sepharose 6B purification 
Sepharose 6B resin (Sigma, USA) was washed with H2O and then buffer A (Table 3.12) 
by centrifuging and replacing the supernatant with the next wash buffer and centrifuged 
at 500 x g, 10 min, at 4 oC in a 4K15 Sigma Centrifuge.  The lysate was incubated with 
the resin for 10 min at 22 oC, rotating end over end, and centrifuged at 500 x g, 10 min, 
at 4 oC in a 4K15 Sigma Centrifuge.   
 
3.6.4.3. Ni NTA purification 
Nickel-charged nitrilotriacetic acid (NTA) cross linked to agarose was used to purify 
6xHis-tagged proteins under native and denaturing conditions (QIAGEN, Hilden, 
Germany). Eight ml 50 % slurry was washed with H2O and equilibrated with buffer A 
(Table 3.12) (centrifuge at 500 x g, 10 min, at 4 oC in a 4K15 Sigma Centrifuge).  The 
lysate post Sepharose B6 incubation was incubated for 1 h at 22 oC and then centrifuged 
at 500 x g, for 10 min, at 4 oC in a 4K15 Sigma Centrifuge. The Ni NTA agarose was 
then washed three times with 50 ml buffer A (centrifuging at 500 x g, 10 min, at 4 oC in 
a 4K15 Sigma Centrifuge in between to exchange washes). On the final wash the Ni 
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NTA agarose was transferred to a column with filter to prevent any Ni NTA passing 
through. The Ni NTA agraose was washed with 20 ml Wash buffer, 20 ml Wash buffer 
with 20 mM Imizadole and the 10 ml Elution buffer. The eluted material was dialysed 
using 3.5 KDa Slide-A-Lyzed dialysis cassettes (Thermo, Rockford, USA) or 
SnakeSkin Tubing (Thermo, Rockford, USA) against three 1L changes of buffer A, at 4 
oC. During the purification protocol samples for SDS PAGE were taken to monitor the 
presence of recombinant proteins.  
 
3.6.4.4. Cleavage of His tag for rISG65-1 
1.4 mg of His-rISG65 was incubated with 100 µl of 1 mg/ml His-TEV protease (a kind 
gift from Professor William Hunter, University of Dundee) at 22 oC for 3 h. Aliquots of 
the supernatant was taken every 1 h and were run on a SDS PAGE gel to gauge the 
cleavage efficiency.   
 
3.6.4.5. Size exclusion chromatography  
Purified recombinant proteins were concentrated, if necessary, to 2-3 mg/ml (final 
volume 0.5 ml) by using Vivaspin20 concentrator (Sartorius, Goettingen, Germany) 
with a molecular weight cut-off of 10 kDa. The Superose 12 10/300 GL (GE 
Healthcare, Sweden) size exclusion chromatography column was calibrated in buffer A 
with standard proteins, Bovine serum albumin (BSA) (4 mg/ml) and Cytochrome C (0.5 
mg/ml). Concentrated recombinant proteins were loaded on the pre-equilibrated 
Superose 12 column via an AKTA Purifier system (GE Healthcare). The column was 
pre-equilibrated with buffer A (Table 3.12) and the column was eluted with 1.5 column 
volumes buffer A at a flow rate of 0.5 ml/min. Aliquots from the fractions of interest 
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were loaded on a SDS-PAGE gel and the proteins content staining assessed by 
Coomassie.  
 
3.6.4.6. GST tagged recombinant proteins 
The protocols used are the same recombinant expression as those used in (Sections 3.6.4 
to 3.6.4.1). Following from cell lysis, clarified supernatant lysate was applied to pre-
equilibrated, with Buffer A, Sepharose Glutathione Fast Flow beads (GE Healthcare) 
rotating for 2 h at 4 oC.  The material was applied to a 10 ml disposable column 
(BioRad) and the beads washed with 25 column volumes of buffer A. GST tagged 
recombinant proteins were eluted with 10 ml buffer A containing 10 mM reduced 
glutathione. 1 ml fractions were collected and aliquots were loaded on SDS PAGE and 
protein was quantified by Absorbance at 280 nm.  
 
3.6.5. Protein concentration determination 
Protein concentrations were estimated using a BioRad assay using BSA as a standard 
and following the manufacturer’s instructions (BioRad). Protein solutions were also 
estimated by Absorbance at 280 nm and calculating protein concentration based on 
protein’s predicted extinction coefficient.    
 
3.7. Enzyme linked Immunosorbent Assay (ELISA) plates 
White, un-treated 96 well plates (Costar, Corning, USA, #3370) were coated with 2 
µg/ml protein solution at 50 µl/well for 16 h at 4 oC.  The proteins (recombinant or 
native) were diluted in coating buffer (0.05 M NaHCO3, pH 9.6). Coating solution was 
removed and wells were blocked with 200 µl/well PBS containing 5% (w/v) BSA, for 3 
h at 22 oC or 16 h at 4 oC. Plates were stored at 4oC and used within 24 h.   ELISA 
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measurements were made with both pooled and individual serum samples. The pooled 
sera were diluted to 1:60 in 50 % (w/v) glycerol, PBS and 1 % (w/v) BSA and stored at 
-20 oC. For the ELISA assay used for the individual sera, the 1:60 diluted samples were 
further diluted to 1:1000 immediately before use.  
 
3.7.1. Serum storage 
Individual patients’ serum and pooled serum samples were diluted to 1:60 and stored at 
-20 oC in a 96 well 0.5 ml block (Greiner, Germany) containing PBS, 1% (w/v) BSA 
and 50 % (w/v) glycerol (5 µl serum aliquot diluted in 295 µl solution). Only the first 
three columns of each 96 well block was occupied due to the program used for liquid 
handling (Section 3.3.2).   
 
3.7.2. Adaption for liquid handling device (LHD) 
The LHD transferred the 1:60 diluted sera to the dilution block for further serial 
dilutions (Bio-Tek, Precision). Aliquots (50 µl) of serial serum dilutions were 
transferred in triplicate to the ELISA antigen plates. 
 
3.7.3. Pooled serum dilution for ELISA plates 
Serum pools were made by combining patients sera from: 1st stage T. b. gambiense 
patients (n=10), 2nd stage T. b. gambiense patients (n=40) and matched uninfected 
patients (n=50); and from 1st stage T. b. rhodesiense patients (n=5), 2nd stage T. b. 
rhodesiense patients (n=20) and matched uninfected patients (n=25).  The 1:60 diluted 
pooled sera were further diluted to 1:1000 in PBS, 0.1 % (w/v) BSA and then serially 
diluted (doubling dilutions) to 1:32,000 by LHD into a 0.5 ml 96 well block (Greiner, 
Germany). Aliquots of the dilutions (50 µl) are then transferred to antigen plates (n=3). 
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3.7.4. Individual sera dilution for ELISA plates  
Individual serum samples were diluted to 1:60 in the serum blocks. The LHD further 
diluted the 1:60 sera to 1:1000 in PBS, 0.1 % (w/v) BSA and then serially diluted, in 
doubling dilutions, to 1:8000 or carried out a further one dilution step to 1:5000. 
Aliquots of 50 µl were transferred to the antigen plates (n=3). 
 
3.7.5. ELISA  
Sera were incubated for 1 h at room temperature, aspirated and 150 µl ELISA wash 
buffer (PBS, 0.1 % (w/v) BSA) was added to each well by the LHD, left for 10 min and 
aspirated. This wash cycle was performed three times. Biotinylated goat anti-human-
IgG (Jackson Immunoresearch, USA) (re-constituted to 1 mg/ml) was diluted to 1:5000 
and 50 µl aliquots were applied to each well. After 1 h incubation at room temperature 
the secondary antibody solution was removed and wells were washed three times, as 
described above. Horseradish peroxidase (HRP) conjugated to NeutrAvidin (Sigma, St 
Louis, USA) was diluted to 1:4000 and applied to the wells (50 µl/well) for 1 h at room 
temperature. Wells were washed as before. Finally, electrogenerated 
chemiluminescence (ECL) Femto substrate (Pierce, Rockford, USA) containing was 
diluted 1:5 according to the manufacturer’s instructions (i.e., 0.5 ml solution A, 0.5 ml 
solution B with 4 ml PBS) and 50 µl/well was added. Plates were read using an 
Envision plate reader after 2.5 min substrate incubation at 22 oC.  
 
3.7.6. Quantification of IgG in human serum 
IgG quantification kit was used and manufacturer’s instructions were followed 
(Mabtech, Sweden). Briefly, monoclonal anti-human IgG were diluted to 2 µg/ml in 
PBS and coated in wells for 16 h at 4 °C (Coatar clear 96 well plates). Coating solution 
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was removed and wells were washed 3 times with PBS 0.05 % (w/v) Tween 20 and 
blocked for 16 h at 4°C with PBS, 1 % (w/v) BSA. Human serum samples were diluted 
1:60,000 and 1:80,000 and applied in duplicate to the ELISA plates. Serum dilutions 
were incubated with the plate for 1 h and wells were washed as before. A second 
monoclonal anti-human IgG conjugated with Alkaline Phosphatase (AP) was diluted 
1:1000 in PBS and incubated with wells for 1 h. Colourmetric AP substrate 
(SigmaFAST, Sigma, St Louis, USA) was added to the wells and the plate was read 
after 30 min at 595 nm wavelength.   
 
3.8. Lateral flow assay 
Steven Wall at British Biocell International (BBI) was responsible for the design and 
manufacture of the lateral flow test prototypes.  
 
3.8.1. Lateral flow pooled sera optimisation 
Serum aliquots (0.625 to 20 µl) were diluted, if necessary, to a final volume of 20 µl 
PBS and applied to the sample pad. Chase buffer (80 µl of PBS) was added to the 
sample pad and the test was allowed to develop for 30 min. The test line was visually 
scored, based on band intensity, and the device was opened and the sample pads (at the 
top and bottom of the nitrocellulose membrane) were removed to prevent backflow. The 
lateral flow tests were photographed and scanned using a densitometer (CAMAG, at 
BBI facility). 
 
3.8.2. Lateral flow buffer optimisation 
Serum aliquots (5 µl) were diluted in 15 µl PBS and applied to the sample pad. One of 
three chase buffers was then applied to the sample pad; options included, i) PBS, ii) 
3. MATERIALS AND METHODS                                                                               44 
 
 
PBS, 0.05 % (w/v) Tween 20, and iii) PBS, 1 % (w/v) BSA. The test was processed as 
described in Section 3.8.1. 
 
3.8.3. Randomisation of sera 
Sera were randomised by a member of the University of Dundee Tissue Bank. Forty T. 
b. gambiense infected patients’ sera and forty T. b. gambiense uninfected patients’ sera 
were randomly selected from the fifty T. b. gambiense infected and fifty uninfected 
WHO patient sera. These eighty serum samples were then randomised and coded.  
 
3.8.4. Randomised lateral flow trial  
The coded randomised sera aliquots (5 µ) were diluted in 15 µl PBS and were applied to 
the sample pad, followed by 80 µl PBS, 0.05 % (w/v) Tween 20. The tests were 
processed as described in Section 3.8.1. 
 
3.8.5. Cattle sera source 
There were two groups of cattle sera used the first were kind gifts from Onderstepoort 
Veterinary Institute (OVI) (South Africa) and contained non-infected calves (n=3), 
calves infected with a highly virulent strain of T. congolense (n=5) and calves infected 
with a low virulent strain of T. congolense (n=8). The second group of cattle sera were 
kind gifts from Philippe Büscher (ITM) and represent samples taken pre-infection and 
post-infection of 5 calves infected with T. congolense and the same for 5 calves infected 
with T. vivax.  
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3.8.6. Cattle sera lateral flow  
Pooled sera aliquots (10 µ) were diluted in 10 µl PBS and were applied to the sample 
pad, followed by 80 µl PBS, 0.05 % (w/v) Tween 20. The tests were processed as 
described in Section 3.8.1. 
 
3.9. Carbohydrate antigens 
3.9.1. Consortium for Functional Glycomics (CFG) 
200 µg of protein G purified IgG from pooled infected and control sera (see section 
3.X) were sent to the CFG. A glycol-array was performed with six technical replicates. 
CFG provided us with Excel spreadsheets were returned showing the glycol-array 
output. Infection IgG data were normalised to control IgG data. Structures with a 
normalisation ratio above 5 were considered to indicate an infection specific response.  
 
3.9.2. Synthetic biotinylated structures 
Dmitry Yashunsky synthesised a range of biotinylated Galβ1-4GlcNAcβ1-6Galβ1-
4GlcNAc, structures, ranging from two LacNAc (Galβ1-4GlcNAc) repeats (β1-6 
linked) to five LacNAc repeats.  
 
3.9.3. Carbohydrate ELISA – plating the compound 
To anchor carbohydrate structures to the plate, NeutrAvidin (Thermo, Rockford, USA) 
was diluted to 2 µg/ml in plating buffer and coated at 50 µl/well for 16 h at 4 oC 
(Section 3.x) (Costar, Corning, USA #3370, white non-treated 96 well plates). The 
plates were quickly washed with PBS, 0.1 % (w/v) BSA. The biotinylated-LacNAc 
compounds were diluted in PBS to 1.25 µg/ml and 50 µl aliquots were applied to the 
NeutrAvidin plates for 1 h at 22 oC. The solutions were removed and the wells blocked 
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with 200 µl/well PBS, 0.1 % (w/v) BSA and 0.5 µg/ml biotin for 1 h at 22 oC. Plates 
were further blocked with PBS, 5 % (w/v) BSA for 1 h at 22 oC.  Plates were used 
immediately or stored at 4 oC for up to 16 h.  
 
3.9.4. Pooled and individual sera dilutions for carbohydrate ELISA 
Similar to Section 3.7.3 and 3.7.4, however sera were diluted from 1:60 to 1:500 and 
serially diluted to 1:16,000 (doubling dilutions). For pooled sera ELISAs, the ELISA 
plates were washed 3 times with PBS 0.1% (w/v) BSA.  Goat anti-human IgM+ 
IgG+IgA conjugated HRP (Jackson ImmunoResearch, USA) was diluted to 1:5000 in 
PBS 0.1% (w/v) BSA, and was incubated with the wells for 1 h. Wells were washed 3 
time as describe above, and ECL ELISA substrate was applied to the plates as described 
in section 3.7.5. For the individual sera ELISA screen, sera were diluted 1:500 in PBS 
0.1% (w/v) BSA and applied to plates for 1 h. Wells were washed 3 times with PBS 0.1 
% (w/v) BSA. Either; goat anti-human IgG+IgM+IgA conjugated to HRP, goat anti-
human IgG conjugated to HRP (Jackson ImmunoResearch, USA ) or goat anti-human 
IgM conjugated with HRP (Jackson ImmunoResearch, USA) were diluted to 1:5000 
and applied to wells. Plates were processed as described in 3.7.5.  
 
3.10. Statistics 
Bar graphs and scatter plots (x by y) were generated by Microsoft Excel. Box plots, 
Receiver Operator Characteristic (ROC) curves, antigen scatter plots (y axis only) were 
generated by SigmaPlot 12. Statistical analysis included Mann-Whitney (Rank Sum 
Test) and Dunn’s post-hoc (Analysis of Variance (ANOVA) on rank) in SigmaPlot 12.  
The P values were recorded for Mann-Whitney with <0.05 set as the cut off for 
statistical significance.  The Q and P values were recorded for Dunn’s post-hoc test 
3. MATERIALS AND METHODS                                                                               47 
 
 
rests. Higher ‘Q’ values indicates the difference between the two groups is statistically 
significant, and less than P=0.05 gives confidence of the statistical significance of the Q 
value, in that the median values among the treatment groups are greater than would be 
expected by chance.  
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4. The identification of immunodiagnostic protein biomarker antigens for African 
trypanosome infections in man. 
 
4.1. Background 
The primary tools available to us for the initial identification of immunodiagnostic 
biomarker antigens were a small number of serum samples from patients infected with 
T. b. gambiense and uninfected (control) patients from the same region. We refer to 
these initial sera as the “identification set”.  In this chapter I will describe how this set 
was used to identify protein antigens recognised by infection sera. An important step in 
this process was to de-select those antigens that were also recognised (and/or non-
specifically bound) by antibodies in the sera of uninfected patients.  The remaining 
infection-specific proteins were then assessed as potential disease-specific diagnostic 
candidates (Chapter 5).  
 
We chose to select the IgG fraction to immunoprecipitate parasite antigens for several 
reasons: Firstly, this is the major antibody fraction of human serum (approximately 75% 
of immunoglobulins) and it is easy to purify on immobilised protein-G. Secondly, IgG 
antibodies tend to have relatively high affinity for their target antigens and relatively 
low non-specific binding, compared to IgM antibodies. Thirdly, preliminary discussions 
with British Biocell International (BBI) (lateral flow specialists) about the prospective 
set-up of a lateral flow test for HAT led to the recommendation that we should make a 
test based on antigens recognised by IgG antibodies rather than IgM antibodies.  
 
As a source of trypanosome antigens for immunoprecipitation, we chose to use T. b. 
brucei total detergent lysate. This was a pragmatic choice, based on the ease with which 
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large quantities of bloodstream form T. b. brucei parasites can be propagated in rodents. 
This choice was also informed by the high degree of similarity between T. b. brucei and 
the human pathogens T. b. gambiense and T. b. rhodesiense and the coverage and 
quality of the T. b. brucei genome sequence (upon which the proteomic identification of 
proteins depends).   
 
4.2. Immunoprecipitation  
Two immunoprecipitation experiments were carried out. 
 
4.2.1. IgG purification, immobilisation and immunoprecipitation 
The IgG fractions were purified by a standard protocol using protein G (Materials and 
Methods), from sera pooled from four T. b. gambiense infected (Table 4.1) and four 
matched uninfected (control) patients (Table 4.2) and from one unmatched control 
serum (Male, age 33). These IgG fractions were then coupled to CNBr-activated 
SepharoseTM (3.3.4). Middle aged male sera were selected for pools and with only four 
individuals matching this description in the control sample selection, the infection 
individuals for pool were chosen based on age similarity with chosen control 
individuals.  
 
In the first immunoprecipitation experiment, aliquots of trypanosome detergent lysate 
(equivalent to 1 x 1010 parasites) were immunoprecipitated with either infection- or 
control-IgG attached to Sepharose 4B and with Sepharose 4B alone. Aliquots (95% of 
eluted proteins corresponding to 9.5 x 109 cell equivalents of trypanosome lysate) were 
analysed by SDS-PAGE (Figure 4.1). The results indicated the elution contained 
significant amounts of IgG heavy and light chain which had leached from the antibody 
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columns, at 55 kDa and 25 kDa, respectively, (lanes A-C) and that the amounts of 
trypanosome protein antigens specifically adsorbed and eluted from the infection-IgG 
Sepharose (lane A) were relatively small. Nevertheless, the bands marked *1 to *5 were 
excised for in-gel tryptic digestion and proteomic analysis. The identities of the main 
components of these bands are shown in Table 4.3, including keratin, which is a 
common contaminant of SDS PAGE gels and proteomics and was disregarded.  These 
data suggested that three T. brucei antigens might be recognised by infection-IgG, 
namely, VSG MITat.1.4, ISG75 and ISG65.  
 
In the second immunoprecipitation experiment, we increased the amounts of 
immobilised IgG from 4 mg to 7.5 mg. We also introduced a step to remove eluted IgG 
heavy and light chains prior to SDS-PAGE analysis. In this experiment, we saw a 
significant increase in the amount of antigens immunoprecipitated (Fig 4.2), suggesting 
that the amount of immobilised antibody had been a limiting factor in the first 
experiment.  
  
4.3. Proteomics 
4.3.1. Identification of tryptic peptides 
The gel slices, marked on Figure 4.2, were alkylated, digested with trypsin and loaded 
on ESI-MS/MS for peptide identification. Peptides were matched to predicted protein 
sequences using MASCOT daemon software, which ranked the identified predicted 
protein sequences with a score, known as the MASCOT score. This ranking algorithm 
takes into account many criteria, including, the peptide coverage of the predicted protein 
sequence and combines with the probability of identifying the peptide compared to 
randomly identifying the peptide.  In many cases proteins were identified with the 
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highest MASCOT score in one gel slice, with smaller MASCOT scores found for the 
same protein in the gel slices above and below.  
 
4.3.2. Protein identification 
A MASCOT score cut off of 50 was used to reject potentially ambiguous protein 
identifications e.g. those identified from a single peptide per protein and/or those with 
relatively low quality MS/MS spectra. We then compared the lists of proteins found 
within each gel slice (Figure 4.3 and for full list see Appendix Figures A1 and A2) and 
selected the 24 protein identifications that occurred only in the infection-IgG eluate 
(Table 4.4). The de-selection of those antigens that also bound to the control-IgG 
Sepharose was crucial in this process.  
 
Of the 24 proteins identified uniquely from the infection-IgG elutions, 11 of them were 
‘hypothetical proteins’ and 7 of the twelve highest MASCOT scored proteins (>200 
MASCOT score) were cell surface proteins, e.g., the transferrin receptor, (composed of 
expression site associated gene (ESAG) 6 and ESAG7 proteins), ESAG2 protein, gene-
related to ESAG (GRESAG)4 protein and members of the Invariant Surface 
Glycoproteins (ISG) families ISG64, ISG65 and ISG75. 
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5. Expression, purification and ELISA of recombinant protein antigens 
Diagnostic kits require multi-milligram to gram quantities of diagnostic biomarkers for 
industrial scale manufacture and distribution. A challenge for any immunodiagnostic 
test is the ability to make or synthesise enough material for mass production. Thus, 
there may be excellent candidate antigens, as identified by immunoprecipitation, which 
may not prove feasible for recombinant protein expression. Proteins that are easy to 
express in a soluble form and that are stable and well characterised are needed to 
manufacture tests.  Therefore, our aim was to first assess the ease of protein expression 
of a number of the potential diagnostic antigens identified in chapter 4 and then to 
assess their promise for diagnostic use.  
 
5.1. Protein antigen selection criteria and overview 
The trypanosome proteins that were identified uniquely in infection-IgG 
immunopurified fractions (Table 4.4) were considered for recombinant expression. Of 
these, the proteins with high MASCOT scores were prioritised. The rationale for this 
selection was that, by using an excess of trypanosome lysate in the affinity purification 
step, the amount of an eluted antigen should reflect, to a first approximation, the relative 
amount of antigen-specific immobilised IgG. The latter should, in turn, correspond to 
the immune response to that antigen in infected patients. Using this criterion, the protein 
antigens selected for study were ISG75, ESAG7, GRESAG4, ISG65, ISG64 and 
ESAG6, respectively. 
 
Next, we looked into the likely ease of protein expression of these antigens in E. coli. At 
this stage, we de-selected ESAG6 and ESAG7 because they form a heterodimer (adding 
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the complication of dual-expression) and because successful (but low level) protein 
expression has only been reported in a eukaryotic baculovirus expression system 
(Chaudhri et al., 1994). On the other hand, E. coli recombinant expression of domains 
of ISG75, ISG65 and ISG64 have been reported, either in the literature (Tran et al., 
2008) or by personal communication (Professor Mark Carrington, University of 
Cambridge). Consequently, we selected all three ISGs for protein expression trials. 
Finally, we performed expression trials on the putative extracellular domain of 
GRESAG4, for which there are no literature precedents.  
 
5.2.  Recombinant ISG75 (rISG75) expression  
ISG75 is a cell-surface glycoprotein with a large N-terminal extracellular domain, a 
single transmembrane domain and a short cytoplasmic domain. It was identified by cell-
surface biotinylation (Ziegelbauer and Overath, 1992) and it is estimated to be present at 
about 50,000 copies per cell (Ziegelbauer et al., 1992). The function(s) of ISG75 are 
unknown but it has recently been suggested that it is the specific receptor for the drug 
Suramin and that it shuttles between the cell surface and the endosomal system of the 
parasite (Alsford et al., 2012). 
 
The proteomics experiments described earlier (4.2.1 and 4.3.2) identified T. b. brucei 
ISG75 (Uniprot_Q26769). We took the predicted amino acid sequence for this gene and 
identified the closest relative in the T. b. gambiense protein database (Tbg972.5.320; 99 
% identity). This sequence is, in turn, very similar (92% identical) to another ISG75 
from the EATRO 1125 T. b. brucei strain (gene ID cannot be included at present due to 
the incomplete genome sequencing of the EATRO 1125 T. b. brucei). Figure 5.1 shows 
the recombinant protein sequence (for resides 32-419) which was already available from 
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our collaborator, Professor Mark Carrington and we therefore elected to use this 
recombinant antigen (rISG75-1) for further studies.  
 
However, since the trypanosomatid ISG75 family falls into 2 subgroups (Tran et al., 
2006), we also attempted to express a similar part of another ISG75 belonging to the 
other subgroup (gene identifier Tb927.5.350). The sequence of this ISG75 variant is 
aligned with that of Tbg972.5.330 in (Figure 5.2) and shares 41% identity. Primers were 
designed to PCR amplify part of the Tb427.5.350 gene corresponding to amino acids 30 
to 295 and the PCR product was cloned into a pET15b-TEV vector and then 
transformed into BL21(DE3)RIPL, E. coli cells (3.5-3.6).  
 
Three expression conditions were investigated (Figure 5.3, A) and condition B was 
chosen for a 1L expression and purification trial. Unfortunately, the rISG75-2 was not 
expressed in a soluble form and was found mostly in the insoluble pellet fraction shown 
in Figure 5.3, B. Therefore, we solubilised the pellet material in 6 M Guanidine 
Hydrochloride (GuHCl) buffer to attempt to re-fold it during purification. However the 
protein precipitated when the denaturing agent was removed, either by on-column 
buffer exchange or by overnight dialysis (Figure 5.3, C).  
 
A final attempt was taken to obtain soluble rISG75-2 by sub-cloning it into a modified 
pGEX vector with tobacco etch virus (TEV) protease cleavage site located in between 
the glutathione S-transferase (GST) tag and the protein (kind gift from Jen Fleming). 
The GST-rISG75-2 plasmid was transformed into E. coli and expressed by IPTG 
induction. A 60 kDa protein product was observed by SDS-PAGE and in-gel digestion 
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and proteomics identified it as rISG75-2 sequence (MASCOT score of 459) (Figure 
5.4). 
 
While the GST tag did marginally improve the solubility of rISG75-2, there was not 
enough protein to attempt a TEV proteolysis or for the preparation of ELISA plates. 
Therefore, we decided to discontinue work on rISG75-2 as a potential recombinant 
diagnostic candidate.  
 
5.3. Recombinant GRESAG4 (rGRESAG4) expression 
Gene Related to Expression Site Associated Gene (GRESAG)4 is found on the 
trypanosome cell surface. It has a large N-terminal extracellular domain, a single 
transmembrane domain and a cytoplasmic domain which contains the adenylyl cyclase 
activity (Gould and de Koning, 2011, Bieger and Essen, 2000, Bieger and Essen, 2001).  
GRESAG4 encodes for an adenylyl cyclase that converts adenosine tri-phosphate 
(ATP) to cyclic adenosine monophosphate (cAMP) (Seebeck et al., 2001).  
Recombinant constructs described in the literature represented the catalytic domain 
(Bieger and Essen, 2000, Bieger and Essen, 2001) but not the N-terminal extracellular 
domain which may contain many infection specific epitopes. In contrast some 
mammalian adenylyl cylases lack the extracellular domain and have twelve 
transmembrane domains while others have no transmembrane domains (Seebeck et al., 
2004, Dessauer, 2009, Bieger and Essen, 2000).  
 
The second proteomic experiment identified T. b. brucei GRESAG4 (Tb927.7.7530) 
with a MASCOT score of 1456.  We took the predicted amino acid sequence for this 
gene and identified the closest relative in the T. b. gambiense protein database 
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(Tbg972.4.4530; 87% identity) (Figure 5.5). Primers were designed to PCR amplify the 
part of Tb427.7.7530 corresponding to amino acids 46 to 840 and the PCR product was 
cloned into pET15b-TEV and transformed into BL21(DE3)RIPL E. coli cells (Materials 
and Methods). 
 
5.3.1. Expression and purification trials of rGRESAG4 
Three expression conditions were investigated (Figure 5.6, A) and condition B was 
chosen for 1L expression and purification trial of the protein (Figure 5.6, B). 
Unfortunately, the rGRESAG4 (50-840) protein was not expressed in a soluble form 
and the IPTG-induced 80 kDa protein in the insoluble pellet (Figure 5.6, B, lane 3) was 
identified as GRESAG4 by proteomics (MASCOT score 642).  
 
The GLOBplot program was used to predict regions of disorder in the GRESAG4 full 
length protein sequence and to predict protein sub-domains (Linding et al., 2003). This 
led to the identification of two predicted sub-domains, ‘A’ and ‘B’ (Figure 5.7) within 
the extracellular domain of Tb427.7.7530 GRESAG4 and various constructs of these 
domain were amplified by PCR (Figure 5.7).  The PCR products were then cloned into 
either pET15b-TEV or pGEX-TEV vectors and transformed into E. coli cells 
(BL21(DE3)RIPL).  Attempts to express soluble protein representing GRESAG4 part a 
(corresponding to residues 46-407) and GRESAG4 part b (corresponding to residues 
401-836 and 401-840) were unsucessful in initial expression trials (data not shown). 
However, GRESAG4 part a (G4a) corresponding to residues 50-401 was cloned into 
pGEX-TEV, transformed into BL21(DE3)RIPL cells and was successfully expressed. 
Expression condition C was used for the 1L expression and purification trial of this 
clone.  The co-expressed N-terminal GST tag improved the solubility of G4a (Figure 
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5.8) however there were other protein impurities ranging from 17 to 25 kDa and the 
GST tag could not be cleaved from this G4a fusion protein (data not shown).  
There was not enough G4a fusion protein (<100 µg/ L) to attempt further purification 
by size exclusion. However, despite the 17-25 kDa impurities, we decided there was 
enough protein to make some ELISA plates with which to screen the ‘identification 
serum set’.  
 
5.4. Recombinant ISG65 (rISG65) expression and purification 
ISG65 is a cell surface glycoprotein with a large N-terminal extracellular domain, a 
single transmembrane domain and a short cytoplasmic domain. Similar to ISG75, 
Invariant Surface Glycoprotein 65 (ISG65) was isolated and identified from the 
trypanosome cell surface, and estimated to be present at approximately 70,000 copies 
per cell (Ziegelbauer and Overath, 1993, Ziegelbauer and Overath, 1992).  The 
function(s) of ISG65 are unknown, but recent studies show that ubiquitylation of the C-
terminal intracellular domain is a general mechanism to regulate some trans-membrane 
cell surface proteins (Chung et al., 2008, Leung et al., 2011).   
 
5.4.1. Recombinant ISG65-1  
The proteomics experiments, described in chapter 4, identified T. b. brucei ISG65 
(Uniprot_Q26712) as a potential biomarker. The predicted amino acid sequence was 
taken for this gene and the closest relative in the T. b. gambiense protein database was 
identified (Tbg972.2.1720, 98 % identity).  This sequence is very similar (93 % 
identical) to another T. b. brucei EATRO1125 ISG65 gene 1125d (Figure 5.9) for which 
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a DNA clone (residues 20 to 366) was already available from our collaborator, 
Professor Mark Carrington.       
 
Three expression conditions were trialled (Figure 5.10, A) and condition C was chosen 
for 1L expression and purification (Figure 5.10, B). Purification of rISG65-1 was 
successful with a good yield of soluble protein (14 mg/ L) (Figure 5.10, B). The 
amounts of impurities in the eluate from the first NiNTA purification (Figure 5.10, B, 
lane 7) could be reduced  by applying the eluate to a Sepharose 12 size exclusion 
column (Figure 5.10, D), or by TEV proteolysis followed by purification on a second 
NiNTA column (Figure 5.10, E). Materials from both of these second round 
purifications (i.e., the materials represented in Figure 5.10, D, lanes 8 and 9, and Figure 
5.10, E, lane 6) were used interchangeably for making rISG65-1 ELISA plates (3.7).  
 
5.4.2. Recombinant ISG65-2  
The ISG65 family also falls into 2 subgroups, so we expressed a second recombinant 
ISG65 (rISG65-2) sequence from a similar part of another ISG65 that belongs to the 
other subgroup.  This sequence is derived from another T. b. brucei EATRO 1125 
ISG65 sequence that was made available to us as a DNA clone (residues 31 to 354) by 
our collaborator, Prof. Mark Carrington.  The sequence of this rISG65 is aligned with 
that of Tbg972.2.1720 (its nearest neighbour in the T b. gambiense genome) with which 
it has 65 % identity (Figure 5.11).   
 
The second rISG65 (rISG65-2) construct was transformed into BL21(DE3)RIPL E. coli 
cells.  Three expression conditions were carried out (Figure 5.12, A) and condition C 
was chosen for 1L expression and purification trials (Figure 5.12, B).  The purification 
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of rISG65-2 was successful with most of the rISG65-2 protein being found in the 
soluble fraction (Figure 5.12, B) and a reasonably high yield of 5 mg/ L of culture was 
obtained. The purity of rISG65-2 was enhanced by dialysis and performing a second 
round of NiNTA chromatography using a pre-packed 1 ml NiNTA column and an 
imidazole gradient for elution (Figure 5.12, C).   
 
5.5. Recombinant ISG64 (rISG64) expression and purification 
ISG64 is a cell surface glycoprotein with a large N-terminal extracellular domain but it 
is smaller than ISG65 and ISG75. ISG64 has a single transmembrane domain and a 
short cytoplasmic domain but as yet it has no known function.  
 
5.5.1. Recombinant ISG64-1 
The second proteomic experiment identified T. b. brucei ISG64 (Tb927.5.1410) with a 
MASCOT score of 582. We took the predicted amino acid sequence for this gene and 
identified the closest relative in the T. b. gambiense protein database (Tbg972.5.6550; 
98% identity) (Figure 5.13). The T. b. brucei sequence (Tb427.5.1410) corresponding to 
amino acids 24 to 363 was amplified by PCR and the product was cloned into pET15b-
TEV and transformed into BL21(DE3)RIPL E. coli cells (3.5-3.6).    
 
Three expression conditions were trialled (Figure 5.14, A) and condition C was chosen 
for 1L expression and purification (Figure 5.14, B). Purification resulted in a yield of 
6.5 mg/L. The lower band in the SDS PAGE profile of the purified rISG64 (Figure 5.14, 
B, lane 8) is similar to that found in the rISG65-1 purification (Figure 5.10) and it was a 
proteolysis product as confirmed by proteomics (data not shown). Attempts to separate 
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the 30 kDa component from the 40kDa protein were unsuccessful, as shown by SDS-
PAGE analysis of fractions collected after a Sepherose 12 size exclusion column 
(Figure 5.14, D). The rISG64-1 material used for making ELISA plates therefore 
contained both the 40 and 30 kDa components.  
 
5.5.2. Recombinant ISG64-2 
Similar to the ISG75 and ISG65 families, ISG64 also falls into 2 subgroups. We 
therefore expressed and purified similar parts of another ISG64 belonging to the other 
sub group (gene identifier Tb927.5.1390). This sequence is derived from another T. b. 
brucei EATRO 1125 ISG64 sequence which was made available to us as two DNA 
clones (residues 20 to 355, and 20 to 292) by our collaborator, Prof. Mark Carrington.  
The sequences of these rISG64-2 and rISG64-3 constructs were aligned with that of 
Tbg972.5.6550 and have 70% and 66% identity, respectively (Figure 5.15). 
 
Three expression conditions were trialled for rISG64-2 (Figure 5.16, A) and condition 
A was chosen for 1L expression and purification (Figure 5.16, B). Purification of 
rISG64-2 was successful with a large soluble yield of 5.7 mg/ L (Figure 5.16, B).  The 
NiNTA column elution (Figure 5.16, B lane 7) was applied to a Sepharose 12 size 
exclusion column (Figure 5.16, C), and fractions containing protein were analysed by 
SDS-PAGE (Figure 5.16, D).  
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5.5.3. Recombinant ISG64-3 
The final recombinant protein we chose to make was rISG64-3. Three expression 
conditions were trialled (Figure 5.17, A) and condition B was chosen for 1L expression 
and purification (Figure 5.17, B). Purification of rISG64-3 was successful with a large 
soluble yield of 8.6 mg/ L obtained (Figure 5.17, B).  The elution (Figure 5.17, B, lane 
7) was applied to a Sepharose 12 size exclusion column (Figure 5.17, C), and the 
fractions containing protein were analysed by SDS-PAGE (Figure 5.17, D).  
 
5.6. Recombinant protein biomarker assessment  
While recombinant protein domains have the same primary amino acid sequence as the 
equivalent part of the native protein, there is no guarantee that a recombinant protein 
will bind antibodies raised to the whole native protein. For example, the recombinant 
protein may not be appropriately folded to present native conformational epitopes 
and/or the recombinant protein domain may exclude the immunodominant part of the 
native molecule. Therefore, before any recombinant proteins are considered for lateral 
flow device development, they are first assessed for immunoreactivity with patient sera 
by a complementary method. The most commonly used method to quantify antibody 
titres directed to different proteins is the Enzyme Linked Immunosorbent Assay 
(ELISA).  
 
A representative and founder of the lateral flow company (now called BBI - Richard 
Lamotte) advised us in the early stages of this project to aim to exploit patient’s IgG 
rather than IgM responses. This is due to the principle that, in general, IgGs are bivalent 
molecules of relatively high affinity whereas IgMs are decavalent low affinity 
molecules that may cause high background signals in lateral flow assays. Therefore, our 
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immunoprecipitation experiments utilised the IgG fraction from sera to identify 
potential immunodiagnostic biomarker antigens and the ELISAs described in this 
chapter were set up to measure the patient’s IgG response to the potential recombinant 
biomarkers.  
 
The ELISA method and principles are described in more detail in the Materials and 
Methods section (3.7 - 3.7.5). Briefly, typically 200 ng of recombinant protein are 
adsorbed to each well and the plates are then blocked with PBS containing 5% BSA, to 
reduce non-specific antibody binding. Patient’s sera are diluted in PBS, 0.1 % BSA and 
added to the plate for 1 h. The plates are washed three times with PBS containing 0.1% 
BSA. The human antibodies that bound to the plate are then detected using enzyme-
linked (horse radish peroxidase, HRP) binding molecules and a chemiluminescence 
substrate, with the resulting signal measured by a plate reader (Envision). Some 
optimisation of the detection system was performed. 
 
5.7. Assessment of diagnostic potential of recombinant antigens by ELISA using 
pooled human sera. 
Recombinant antigens; rISG64, rISG65 and rISG75 all gave high infection specific 
ELISA signals, with low non-infected signals at serum dilutions of 1:1000 (Figure 
5.18). GST-G4a was abandoned at this stage because it had poor infection versus non-
infection discrimination (Figure 5.18). From these results, all the recombinant ISG 
proteins were taken forward to be screened against the individual sera (Chapter 6).  
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6.  Immunodiagnostic biomarker antigen validation  
6.1.   Validation human serum sample set 
In addition to the ‘identification serum set’ (n=18) used in Chapter 5 to select potential 
recombinant immunodiagnostic antigens for further study, we obtained a larger set of 
human serum samples (n= 145) from the WHO HAT specimen bank.  We refer to this 
set as the ‘validation serum set’. These samples contained sera from 1st stage T. b. 
gambiense patients (n=10), 2nd stage T. b. gambiense patients (n=40) and matched 
uninfected patients (n=50); and from 1st stage T. b. rhodesiense patients (n=5), 2nd stage 
T. b. rhodesiense patients (n=20) and matched uninfected patients (n=25). Anonymised 
clinical data are also available on these samples (Appendix, Tables A3-A10). In this 
Chapter, I describe how these sera were used with the recombinant antigens selected in 
Chapter 5 and some native VSG antigens to select antigens for the development of 
lateral flow devices.  
 
6.2.   Adaptation of the ELISA procedure to a liquid handling device  
The general ELISA procedure was adapted for a liquid handling device, which made the 
procedure much more time efficient, reduced pipetting error and improved inter-plate 
and intra-plate consistency. A number of liquid handling devices were available for 
trial. Assessment of each liquid handling device was carried out by simulating the serial 
dilution step used in the ELISA using OrangeG dye in 50 % glycerol stored at – 20 oC 
and measuring the variation by Coefficient of Variation expressed as a percentage  (% 
CV). CV is calculated by dividing the standard deviation by the mean and multiplying 
by 100 to give the % CV. Assays or systems that have a low variation will have a low % 
CV.  The Precision liquid handling device performed consistently well within a CV of 
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8-10 %  for both intra-plate and inter-plate variation, while the other liquid handling 
devices (Rainin and Hydra) were either no better or worse by this criterion. The 
Precision liquid handling device was also compatible with use in a laminar flow hood, 
providing protection from potential exposure to human serum aerosols. For these 
reasons, we adopted the Precision liquid handling device, which was kindly made 
available for us to use by Professor Alan Fairlamb (Biological Chemistry and Drug 
Discovery, College of Life Sciences, University of Dundee). 
 
6.3.   IgG quantification of human serum samples 
Alongside the individual sera screens against recombinant antigens, the IgG in each 
serum sample was quantified using a commercial ELISA kit to check whether infection 
and control sera contained comparable levels of total IgG (3.7.6).  The ELISA data were 
expressed as box plots (Figure 6.1) and were further statistically analysed by Mann-
Whitney Rank test for comparison between infection and control IgG levels and by 
Dunn’s post-hoc for comparison between 1st stage with 2nd stage and with control.   
There was no statistical significance for the comparison between T. b. gambiense 
infection and control IgG concentration by the Mann-Whitney Rank test (p=0.110); 
however there was statistical significance when comparing the IgG concentration from 
T. b. rhodesiense infected and control groups (p=<0.001).  Further statistical analysis 
was carried out by Dunn’s post-hoc to see if there was any significance between three 
groups (1st stage, 2nd stage and control).  As inferred by the T. b. gambiense box plot 
(Figure 6.1, a) the 1st stage patients (Q=2.807; P=<0.05) have statistical significant 
higher IgG levels than compare with control and 2nd stage groups. There was no 
statistical significance difference between 2nd stage and control groups from the T. b. 
gambiense sera set. Conversely, the 2nd stage T. b. rhodesiense patient group have 
6. RESULTS                                                                                                                   65 
 
 
higher IgG concentrations (Q=3.720; P=<0.05) compared with patients from the 1st 
stage and control groups (Figure 6.1, b).   
 
Larger values of ‘Q’ indicate the difference between the two groups being compared is 
statistically significant, with the P values less than 0.05 indicating the likelihood of 
being incorrect of the significant difference is less than 5%. These statistical results 
indicate a significant difference of the IgG concentration of the 1st stage T. b. gambiense 
and 2nd stage T. b. rhodesiense patient groups compared to their respective control 
groups; however this is data from a single experiment and needs to be repeated before 
assigning biological significance.  The purpose of this experiment was to assure us the 
infection-specific IgG titres to recombinant proteins are due to specific antibodies and 
not simply to increased total IgG concentrations in infected patients.  The ratio of 
highest of infection serum IgG concentration to lowest control serum IgG concentration 
is less than 2-fold, which is unlikely to significantly bias ELISA and other 
immunodiagnostic read-outs with respect to determining a positive or negative serology. 
  
6.4.  Pooled sera screen with recombinant proteins 
Before performing ELISA measurement with all of the individual sera, we looked at the 
relative performance of the different recombinant antigen ELISA plates using pooled 
sera from the validation set. Purified recombinant proteins (described in Chapter 5) 
were applied to ELISA plates (3.7) and screened against pooled T. b. gambiense and T. 
b. rhodesiense, 1st and 2nd stage infection and control patient sera.  
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6.4.1. T. b. gambiense pool results 
The pooled T. b. gambiense 1st stage and 2nd stage infection sera and pooled matched 
control sera were diluted to 1:1000 and applied to ELISA plates coated with the 
different recombinant antigens. These experiments were carried out in triplicate and the 
mean signal ± 1 standard deviation are shown in Figure 6.2. All of the recombinant 
rISG65 and rISG64 protein constructs showed good separation of signal between the 
infection and control pools, for both 1st and 2nd stage disease. The rISG75 results were 
disappointing and we considered de-selecting this antigen for T. b. gambiense infection 
detection at this point. However we were aware that ISG75 has been described as a 
potential diagnostic antigen by others (Tran et al., 2009, Tran et al., 2008) and we 
elected to retain it for further analysis.  
 
6.4.2. T. b. rhodesiense pool results  
Identical experiments to section 6.4.1 were performed using the pooled T. b. 
rhodesiense 1st stage and 2nd stage infection sera and pooled matched control sera. None 
of the antigens performed well with 1st stage T. b. rhodesiense sera, with the exception 
of rISG75 (Fig 6.2). However, we found later that this was a due to single individual 
with an extraordinarily high antibody titre for rISG75 and we therefore consider this to 
be an anomalous result. Overall, the rISG65 constructs performed better than the 
rISG64 constructs with 2nd stage sera but the results were not as good as with the T. b. 
gambiense infection sera. 
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6.5. Individual sera screen with recombinant proteins 
A good potential diagnostic biomarker is one that elicits antibody response in all 
infected patients.  To test for this, all 163 available individual sera were serially diluted 
from 1:1000 to 1:8000 (doubling dilutions) or diluted 1:000 to 1:5000 in a single 
dilution step and applied in triplicate to ELISA plates coated with the recombinant 
proteins selected for further assessment (i.e., rISG64-1, rISG64-2, rISG64-3, rISG65-1, 
rISG65-2 and rISG75). Data shown below are for the results with 1:1000 dilutions of 
the sera and are considered separately with respect to diagnostic potential for T. b. 
gambiense and T. b. rhodesiense infections.  
 
6.5.1. Results with T. b. gambiense infection and matched control sera 
The individual patient sera were screened against the six selected rISG proteins and the 
results are shown in bar charts representing the ELISA read outs of each patient’s 
antibody titres to each recombinant protein (Figure 6.3 and 6.4). These data illustrate 
that there is heterogeneity in the way that individual sera react with the recombinant 
antigens.  For example, a few patient sera react strongly to both rISG65s but only 
weakly to the ISG64s (Figure 6.4). It is clear from all of the data representations that 
rISG75 gives many false positives (that are in some cases are higher than the control 
signals (Figure 6.4)) confirming the data using the pooled sera and suggesting that this 
recombinant antigen is not suitable for the development of an immunodiagnostic test.  
These data are also broken down into 1st stage and 2nd stage infection versus control 
data as box plots (Figure 6.5, a-f) to provide a more convenient way of assessing the 
ELISA data for each recombinant protein. As inferred by the box plots the Dunn’s Post-
Hoc test supports the observation that in all cases, apart from ISG75, 1st stage and 2nd 
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stage sera contain statically significant more IgG to the recombinant antigens compare 
to control (data not shown). In the case of ISG75, only the 2nd stage group of patients 
had statistically significant higher levels of IgG directed to rISG75-1 compared to 
control (Q=4.616, P=<0.05) and there was no statistical significance between 1st stage 
and control.  The potential of antigens to stage the infection was tested by looking for 
statistical significance between the ELISA signals of 1st and 2nd stage groups. For all 
recombinant antigens there was no significant difference between IgG titres between the 
1st and 2nd stage groups as determined by Dunn’s post-hoc test (data not shown).    
The heat map (Figure 6.5, g) is a convenient way to give an overall impression of all the 
ELISA data, emphasising the heterogeneity of each individual’s antibody response to 
each protein. The results are also collated as scatter plots of signals for all (stage 1 and 
stage 2) infection versus control sera against recombinant antigen type (Figure 6.6).  
 
A Receiver Operator Characteristic (ROC) curve was performed to calculate sensitivity 
on the y axis and specificity on the x-axis (Table 6.1). The area under the ROC curve 
can then be used to identify the best diagnostic candidate, an area under the ROC curve 
of 1 is the best possible outcome, which corresponds to 100 % sensitivity and 
specificity.   
 
As predicted, the rISG75 protein performs badly as a potential diagnostic biomarker 
with an area under the ROC curve of 0.75, whereas rISG65-1 and rISG64-1 performed 
very well with areas under the ROC curve of 0.99 and 0.98, respectively (Figure 6.7). 
As a result of this data, and because we had a high recombinant yield of this protein, we 
selected rISG65-1 to be developed in lateral flow format test for T. b. gambiense 
infections. 
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6.5.2. Results with T. b. rhodesiense infection and matched control sera 
The individual ELISA data for T. b. rhodesiense patients are displayed in bar graphs 
(Figure 6.8 and 6.9), as box plots, combined in a heat map (Figure 6.10) and as a scatter 
plot (Figure 6.11). The bar graphs show each individual’s IgG antibodies to each 
recombinant protein. The box plots show the disease stage-specific effects where, in the 
cases of rISG65-1 and rISG64-3, there appears to be little difference between 1st stage 
and control patient sera. Indeed this observation is supported by statistical analysis 
(Dunn’s post-hoc) where only the 2nd stage group for all antigens were statistically 
significant (data not shown). In addition to this Dunn’s post hoc test is unable to prove 
statistical significance for the 1st stage group with control group, emphasising there is 
no antigen that can discriminate between infection with control with regards to this 
group 1st stage patients (data not shown).     
 
The heat map shows the patient’s antibody/antigen profile, with most patients in 2nd 
stage displaying IgG reactivity to at least two or more recombinant antigens.   
Recombinant ISG65-2 was the only antigen that produced a measurable infection-
specific IgG signal in most patient sera; however rISG65-2 is also recognised by a small 
number of non-infected patients. Two non-infected patients’ sera, CR41 and CR50, 
displayed similar IgG infection-antigen profiles by recognising two or more antigens 
which raised the question as to whether these patients were really uninfected at the time 
of sampling. In any case, if we assume the clinical metadata with the serum samples is 
correct, we can only conclude that for T. b. rhodesiense infections there is no obvious 
candidate for a diagnostic antigen among those tested here, with the limited number of 
serum samples we had available. 
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The ROC analysis, in particular the area under the ROC curve, indicates that the best 
distinguishing recombinant antigen is rISG64-3 (A=0.87) (Figure 6.12), closely 
followed by rISG65-2 and rISG64-2, both of which have areas of A=0.86 with the 
sensitivity and specificity scores recorded in Table 6.2.  
 
6.6.  Summary of differences between T. b. gambiense and T. b. rhodesiense patient 
serum immunoreactivities 
Comparison of the immunoreactivities of T. b. gambiense and T. b. rhodesiense 
infection sera indicate some significant differences. Thus, T. b. gambiense infected 
patient sera appear to show greater response to rISG65-1 and rISG64-1, whereas the T. 
b. rhodesiense infected patient sera appear to show greater response to rISG65-2 and 
rISG64-3. The T. b. gambiense first stage patients generally show antibody response 
towards many of the recombinant antigens, whereas in T. b. rhodesiense first stage 
patients appear to have fewer specific antibodies in these tests. As T. b. rhodesiense is 
thought to be essentially genetically identical to T. b. brucei (with the notable exception 
of the serum resistance antigen (SRA) in the T. b. rhodesiense genome (De Greef and 
Hamers, 1994)) the relatively poor immunoreactivity of the T. b. rhodesiense infection 
sera to the recombinant ISG antigens presumably reflects other factors. Indeed, the 
greater immunoreactivity in T. b. gambiense infection sera may reflect the significantly 
more chronic nature of these infections. This greater temporal exposure may lend itself 
to higher IgG titres against the parasite antigens. The results encouraged us to pursue 
rISG65-1 for lateral flow device development as it had the best properties for T. b. 
gambiense detection. Also it is the easiest to express and purify and has some diagnostic 
potential for T. b. rhodesiense. 
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6.7.  Native T. brucei Variant Surface Glycoprotein (VSG) screen 
In addition to the recombinant protein screens, we screened four native T. b. brucei 
variant surface glycoproteins (VSGs). For these studies, we used the conveniently 
purified soluble form VSG (sVSG) that is formed upon trypanosome lysis by the action 
of endogenous GPI-PLC on the VSG glycosylphosphatidylinositol (GPI) membrane 
anchor (Ferguson et al., 1985). Part of the rationale for this study was that a 
carbohydrate epitope called the cross-reacting determinant (CRD) (Cross, 1979), 
revealed by GPI-PLC mediated release of the VSG coat from dying trypanosomes 
(Zamze et al., 1988), might elicit an anti-CRD response in all infected patients 
regardless of the VSG variants experienced in individual infections. We therefore 
wanted to test if a collection of different sVSGs available in our laboratory, each 
containing the CRD, could react with antibodies in our human host sera samples. As 
will be described, we did not find evidence of significant anti-CRD antibody responses 
but we did find very high titres of IgG antibody against one of the VSGs 
 
6.7.1. Screens for anti-CRD and anti-VSG antibodies in infection sera.  
Four purified sVSG variants (117, 118, 121 and 221) were kindly provided by Dr 
Angela Mehlert. ELISA plates were created for each one and serial dilutions of the 
pooled validation sera were analysed for IgG immunoreactivity to them (Figure 6.13).  
None of the infection sera showed significant reactivity to sVSG121, compared to the 
matched control sera, whereas sVSG221, sVSG117 and to a lesser extent sVSG118, 
showed reasonable reactivity to the pooled T. b rhodesiense infection sera (Figure 6.14). 
The same profile was seen for the pooled T. b gambiense infection sera, except that the 
immunoreactivity to sVSG117 was exceptionally strong. From these data, we concluded 
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that the weak reactivity to sVSG121 indicates that the majority of the immunoreactivity 
to the other sVSGs must be due to anti-peptide antibodies rather than anti-CRD 
antibodies. We followed up these results by investigating the potential of sVSG117 as a 
diagnostic biomarker antigen for T. b. gambiense infections.  
 
6.7.2. Screen of individual sera against sVSG117 and combined sVSG117 and 
rISG65-1 ELISA plates.  
Soluble VSG117 was further screened against the individual T. b. gambiense patient 
sera to assess whether the high antibody titres in the pooled T. b. gambiense infection 
sera were due to a small number of hyper-reactive individuals or whether 
immunoreactivity was common to all or most infected patients. We also created ELISA 
plates coated with both sVSG117 and rISG65 to assess whether these might out perform 
the individual antigen ELISA plates. The results of the means of triplicate analyses are 
shown first as bar graphs (Figure 6.15, A) and scatter plots (Figure 6.15, B) for the 
ELISA signals obtained with 1:1,000 diluted serum samples. These results suggest that 
the sVSG117 plates out performs the rISG65-1 plates and are at least equivalent to the 
combined sVG17 + rISG65 plates. The data are also presented as bar graphs, where the 
error bars represent 1 standard deviation from the mean value.  
 
 
To calculate the sensitivity and specificity of sVSG117 as a potential immunodiagnostic 
biomarker, the data were analysed and showed that the sVSG117 ELISA plate test has 
an area under the ROC curve of 1 (Figure 6.16).  The combined (dual antigen) 
sVSG117 + rISG65-1 ELISA plate had an area under the ROC curve of >0.99 and for 
ELISA plate with rISG-65 alone the value was 0.99.  The sensitivities and specificities 
of the three ELISA plates were also calculated from these data (Table 6.3). This showed 
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that sVSG117 out-preforms rISG65-1 and combined sVSG117 + ISG65-1 as a 
diagnostic antigen for T. b. gambiense infections.  
 
6.8.   Summary  
The key findings up to this point are: 
• The ECL ELISA was shown to be a good assay to validate potential diagnostic 
biomarkers for lateral flow development as the assay is sensitive and 
reproducible.  
• Patients infected with T. b. gambiense have IgG antibodies to many of the 
selected recombinant proteins validating the use of the trypanosome derived 
proteins identified by the immunoprecipitation experiment (chapter 4). 
• Patients infected with T. b. gambiense and T. b. rhodesiense show different IgG 
infection profiles when tested with the recombinant antigen panel.  
• Patients infected with T. b. gambiense have extraordinarily high antibody titres 
towards sVSG117, whereas T. b. rhodesiense patients do not. This may be 
useful when assessing which species patients are infected in areas where T. b. 
gambiense and T. b. rhodesiense co-exist.  This is becoming an increasingly 
likely scenario in some areas in Uganda (Picozzi et al., 2005), or for travellers 
who may have visited areas endemic for both species.  
 
 
 
 
 
 
7. RESULTS                                                                                                                  74 
 
 
7. Lateral flow Test 
The ELISA data suggested that rISG65-1 was the best recombinant antigen to 
differentiate infection and control sera. Therefore, recombinant HIS6-cleaved ISG65-1 
(2 mg) was supplied to Steven Wall at BBInternational (Dundee MediPark), who 
carried out the production of the rISG65 prototype lateral flow test. One hundred un-
optimised lateral flow prototypes were generously provided for us to evaluate. 
While these prototypes were being made a second antigen, sVSG117, was screened and 
found to give better ELISA sensitivity and specificity scores (6.6.2).  The sVSG117 
glycoprotein was therefore also sent to BBI for development in the lateral flow format. 
We received one hundred un-optimised sVSG117 lateral flow prototypes containing just 
sVSG117 for testing against the human sera. We also received sixteen dual test line 
lateral flow test prototypes that contained both sVSG117 and rISG65 test lines. 
 
7.1.  Lateral flow test description 
The lateral flow approach utilised is not animal species-specific and was identical for 
the rISG65 and sVSG117 lateral flow formats (Figure 7.1). Here, for simplicity, only 
the rISG65-1 lateral flow test is described in detail. The rISG65-1 antigen was both 
immobilised in a band on a nitrocellulose membrane (test band) and coupled to colloidal 
gold and suspended in the sample pad. When the test serum and chase buffer are applied 
to the sample pad, the rISG65-colloidal gold conjugate is resuspended. The liquid is 
drawn across the nitrocellulose membrane towards the receiving sample pad at the top 
of the lateral flow device. During this time, anti-rISG65 antibody in the serum binds to 
the rISG65-gold conjugate and when the antibodies reach the rISG65 test band, one Fab 
arm of the IgG binds to the immobilised rISG65 while the other Fab domain bridges to 
7. RESULTS                                                                                                                  75 
 
 
the rISG65-gold-conjugate. Accumulation of this specific antibody sandwich generates 
a visible test line. The control line is an internal positive control for the lateral flow test 
and does not relate to the infection status of the patient. The final reading of this test 
should be as follows, one band for non-infected sera and two bands for infected sera. 
 
7.1.1. Optimisation  
All optimisation experiments were carried out with the rISG65-1 lateral flow prototype, 
with the final conditions transferred for the sVSG117 lateral flow test.  
 
7.1.1.1.  Volume of sera 
To assess the sensitivity and specificity of the lateral flow assay, different volumes (20 
µl, 10 µl, 5 µl, 2.5 µl and 1.25 µl) of pooled T. b. gambiense infection sera (2nd stage 
patients, n=40) and matched T. b. gambiense non-infection (control) sera (n=50) were 
made up to a final volume of 20 µl with PBS and applied to the sample pads. Chase 
buffer (80 µL) was subsequently applied to sample pads and the lateral flow tests were 
left for 30 min, the tests were photographed and scanned by a laser densitometer 
(Camag) (Figure 7.2).   
 
The test line was still visible using 1.25 µl of pooled infection (2nd stage) T. b. 
gambiense sera, indicating that the rISG65 lateral flow test is very sensitive. However, 
at higher serum concentrations, non-specific binding was observed for the non-infected 
patient pooled sera. Therefore, 5 µl of serum was used for all future lateral flow tests as 
it provided a good compromise between absolute sensitivity and signal to noise ratio. 
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7.1.1.2.  Chase buffer optimisation 
There are limited optimisation procedures that can be carried at this stage in the lab with 
the prototype device, as optimisation should really carried out by the manufacturer 
during product optimisation and feasibility stages. However, we performed some 
attempts to reduce the non-specific binding of the test line by the pooled control sera by 
testing different chase buffers. Aliquots of pooled control sera (5 µl) were added to the 
sample pads followed by 80 µl of either: (1) PBS, (2) PBS, 0.05 % Tween 20 (PBS-
Tw20) or (3) PBS, 0.1 % BSA (PBS-BSA). The lateral flow test is principally a visual 
test so, to assess the background signal at the rISG65-1 test line, 25 people were asked 
to rank the intensity of the test band. Most people chose the lateral flow test with PBS, 
0.05 % Tween 20 chase buffer as having the least signal at the test line. This subjective 
assessment was consistent with the Camag scan results which showed that PBS-BSA 
chase buffer increased the non-specific signal compared to PBS alone, while PBS-Tw20 
reduced it (Figure 7.3). The different chase buffers had negligible effects on the 
development of the control line.   
 
7.1.1.3.  Chase buffer assessment with pooled infection sera 
To check whether the new Tween 20-containing chase buffer compromised the positive 
test line signal with pooled T. b. gambiense infection sera, the PBS-Tw20 chase buffer 
experiment was repeated with the pooled T. b. gambiense infection and control sera. 
The presence of Tween 20 in the chase buffer did not significantly affect the positive or 
control test lines for the T. b. gambiense infection sera but it did improve the signal to 
noise ratio for the test (Figure 7.4). 
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7.1.2. Comparison of the rISG65-1 and sVSG117 lateral flow devices with 
individual sera using visual scoring  
To prevent bias when interpreting test line intensities on the lateral flow tests, we used 
randomised sera. Eighty randomly selected serum samples representing 40 T. b. 
gambiense infected and 40 control sera from the validation sera set (6.1) were 
randomised and re-labelled by a member of the University of Dundee Tissue Bank. 
Serum aliquots (5 µl) were diluted with 15 µl PBS and applied to the sample pads of 
both rISG65-1 and sVSG117 lateral flow devices, followed by the addition of 80 µl 
PBS, 0.05 % Tween 20 and the test line intensities were ranked by eye.  Visual scoring 
took place by comparing and ranking the test lines based on the interpretation by a 
single eyewitness.  The scores were recorded and tests were decoded and grouped by 
infection status.  After visual inspection and scoring, the device cases were broken open, 
the sample pads at both ends were discarded and the nitrocellulose strips containing the 
test line were mounted on squared paper for Camag scanning.  The Camag scanning 
was important as it validated the visual interpretation.  The visual scores and Camag 
scores were plotted against each other in a scatter plot to assess the relationship between 
the scores. It shows a strong correlation between the visual interpretation and the 
densitometer of rISG65-1 which had a R2 value of 0.959 and sVSG117 that had a R2 
value of 0.957 (Figure 7.5).  
 
The rISG65-1 lateral flow tests showed good sensitivity. Using a visual cut-off score of 
2.5, all of the T. b. gambiense infection sera were deemed positive (Figure 7.6 A).  
However, five control sera gave high (≥4) or borderline (≥3) scores, suggesting a 
weakness in the specificity of the rISG65 lateral flow assay. On the other hand, using a 
visual cut-off score of 1, the sVSG117 test showed excellent sensitivity and specificity 
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(100 %) with all control sera having a low signal (≤ 0.5) and all T. b. gambiense 
infection sera producing test line intensities ≥1 (Figure 7.6 B). By adding the rISG65-1 
and sVSG117 visual scores and using a combined cut-off of 6, the combined data also 
gave 100% sensitivity and selectivity (Figure 7.6 C).  
 
7.1.3. Comparison of the rISG65 and sVSG117 lateral flow devices with 
individual sera using densitometer scoring  
Following visual assessment of the test lines on the lateral flow devices, the test and 
control lines were measured using Camag laser, a densitometer, offering less subjective 
analyses of the line intensities (Figure 7.7). For the rISG65-1 devices, using a cut-off of 
255 AU, two of the five false-positive the tests in (Figure. 7.6 A) were resolved 
providing 100 % sensitivity and 92.5 % specificity. Using a cut-off score of 110 AU, 
the sVSG117 gave a single false-negative result or using a cut-off of 75 AU, a single 
false-positive result. By adding together the rISG65-1 and sVSG117 scores and using a 
combined cut-off of 450 AU, the combined data give only a single false-positive result, 
suggesting that a combined antigen test of some sort might improve specificity.  
The mean densitometry scores for the positive sera (Table 7.1) were lower for the 
sVSG117 device than the rISG65-1 device, despite the fact that these same sera gave 
higher titres against sVSG117 than rISG65-1 ELISA plates (6.6.2). In addition, the 
sVSG117 test line appears to be wider and less uniform than the rISG65-1 test line 
(Figure 7.8). This is likely to be a manufacturing issue, since the antigen application 
conditions (e.g., antigen concentration and application buffer), have not yet been 
optimised this far.  
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7.1.4. Comparison of lateral flow and ELISA methods 
Signal-to-nosie ratios were calculated for the ELISA mean values and lateral flow 
densitomery scores for infected and control sera (Table 7.1). Despite the isssues with 
the unoptimised application of the sVSG117 test lines we found that sVSG117 out 
performed rISG65-1 in both tests. The mean infection signal >10 times the mean control 
signal for sVSG117 by ELISA and lateral flow, compared to >4 times the difference 
between the mean values for infected and control signals. One possible explanation for 
some of the variation between the ELISA and lateral flow device data may be that the 
former was set up to detect only IgG responses to the antigens whereas the latter will 
detect any antibody subtype (e.g. IgG and IgM) to the antigens. While the results 
described here suggest that sVSG117 is a good antigen for the diagnosis of T. b. 
gambiense infections, the fact that it is a variant surface glycoprotein suggests to us that 
it is not suitable on its own because VSG genes can be lost from telomeric expression 
sites during duplicative transpostion events in antigenic variation.      
 
7.2.  Preliminary dual band (rISG65-1 plus sVSG117) lateral flow prototype test 
results 
A limited number (n=16) of dual test line lateral flow devices were manufactured, in 
order to carry out a proof-of-concept experiment using pooled T. b. gambiense and T. b. 
rhodesiense sera with matched pooled controls.  As expected, the T. b. gambiense 
infection pooled sera resulted in 3 lines, corresponding to (bottom to top) the rISG65 
test line, the sVSG117 test line and the control line (Figure 7.9).  However, the T. b. 
rhodesiense infection pooled sera only resulted in 2 lines, the rISG65 test line and the 
control line (Figure 7.9). This may be due to T. b. rhodesiense not expressing VSG117, 
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so that patients do not have antibodies against this VSG. While this could be seen as a 
weakness, it also opens up the potential for a dual test line diagnostic that can not only 
diagnose T. b. gambiense and T. b. rhodesiense infections but also differentiate between 
the trypanosome sub-species in geographical areas where the trypanosome species 
overlap. However, considerably more T. b. rhodesiense infection sera need to be 
screened before the potential for anti-sVSG117 immunoreactivity in differential 
diagnosis can be assessed.  
 
7.3.  Preliminary single (rISG65-1) and dual band (rISG65-1 plus sVSG117) lateral 
flow prototype test results with bovine sera 
Because the T. congolense genome contains genes with reasonable homology (up to 
46% sequence similarity) to the T. brucei ISG65 gene family, aliquots of pooled high-
virulence (n=5) and low-virulence (n=8) (Savannah strain) T. congolense infection and 
control bovine sera (n=3) were applied to the rISG65-1 single lateral flow assays.  
Aliquots of pooled T. congolense infection and control (n=5 for each) and pooled T. 
vivax infection and control bovine sera were applied to the dual band (rISG65-1 and 
sVSG117) lateral flow assays. The serum aliquots were mixed with 10 µl PBS before 
application to the sample pads and 80 µl of PBS-Tween 20 chase buffer were used.  
 
The results from the single rISG65 test line suggested cross-reactivity of the T. 
congolense infection sera to the T. brucei rISG65 protein (Figure 7.10). However, the 
test line signal was also rather high for the control sera. Furthermore, the double test 
lines lateral flow devices showed cross-reactivity of the T. vivax and T. congolense 
infection sera to the T. brucei rISG65 protein (Figure 7.11). However the T. congolense 
non-infection (control) signal for the rISG65 test line was also high.  The densitometer 
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readings suggest that for T. vivax and T. congolense infection and control sera there was 
a small amount of immune-reactivity for the T. brucei sVSG117 test line (Figure 7.11).  
From these very preliminary data, we conclude that we need to screen a much larger 
number of T. congolense infection and control sera and optimise the chase buffer to 
reduce non-specific binding to the rISG65-1 test line before we can assess the potential 
of rISG65-1 to detect T. congolense infections in cattle. Indeed, it may be better to 
select potential diagnostic antigens by unbiased proteomics methods to move towards a 
bespoke test for T. congolense cattle infections.  
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8. Results II: Identification and preliminary assessment of carbohydrate antigens 
The African trypanosomes synthesise complex cell-surface glycoconjugates, several of 
which are essential to parasite survival and/or infectivity. Examples for the infective 
bloodstream form of T. brucei include the variant surface glycoprotein (VSG), the 
ESAG6/ESAG7 heterodimeric transferrin receptor (Mehlert et al., 2012, Mehlert and 
Ferguson, 2007, Cross, 1996, Pays and Nolan, 1998, Steverding et al., 1995); the p67 
lysosomal glycoprotein  (Peck et al., 2008) and the membrane-bound histidine acid 
phosphatase TbMBAP1 (Engstler et al., 2005). In addition, bloodstream form T.brucei 
synthesise a family of extremely large and complex poly-N-acetlyllactosamine (poly-
LacNAc) containing N-linked glycans that occur in the flagellar pocket and throughout 
the endosomal/lysosmal system (although the identities of the proteins that carry them is 
still unknown) (Atrih et al., 2005). While most of the N-linked glycan structures made 
by the parasite are identical or similar to those that occur in the mammalian host 
(Izquierdo et al., 2009b, Izquierdo et al., 2009a), and are therefore unlikely to elicit an 
immune response, the giant poly-LacNAc N-linked glycans are extremely unusual. 
Further, we do not yet know the complete repertoire of African trypanosome glycan 
structures, for example novel O-linked and/or phosphate-linked glycans may exist in T. 
brucei, as they do in the related T. cruzi and leishmania parasites (de Macedo et al., 
2010, Mendonça-Previato et al., 2005). We therefore decided to look for evidence of 
anti-carbohydrate antibodies in infected sera.  
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8.1.  Glyco-array studies 
A glyco-array is similar to a DNA microarray except that the spots carry specific glycan 
structures and instead of DNA sequences. Such a glyco-array has been created by The 
Consortium for Functional Glycomics (CFG), and it displays 456 different glycan 
structures. We sent the same IgG fractions pooled from infection and control sera that 
we used in for the proteomics-based antigen identification experiments described in 
Chapter 4 to the CFG. The glyco-arrays were performed as six technical replicates, on 
two separate occasions with different aliquots of the pooled infected (n=4) and matched 
control (n=4) antibodies. The data were provided to us as Excel files and the 
immunoreactivity (mean ± 1 standard deviation) of control IgG were taken away from 
the infection IgG signals and show infection and control specific glycans (Figure 8.1). 
On initial inspection, the infection IgG appeared to have very low titres to most of the 
carbohydrate structures compared to the control IgG. However, we surmised that the 
control IgG had a particularly high titre against the anti-blood group A antigen (Galα1-
3(Fucα1-2)Galβ1-4GlcNAcβ1-3Gal). The data were therefore normalised by simply 
dividing the infection sera signals by the corresponding control sera signals and those 
with values over 5 were selected for further study (Figure 8.2).  
 
Of the ten glycan structures selected in this way, nine (90%) contained at least one 
Galβ1-4GlcNAc (LacNAc) substructure. This represented a significant enrichment of 
LacNAc-containing structures specifically recognised by infection IgG over those on 
the CFG V4.1 glyco-array, where 156 glycan out of 461 glycans (34%) contained 
Galβ1-4GlcNAc in the core structure or in a side chain. This result stimulated our 
interest in assessing whether the unusual giant poly-LacNAc N-linked glycan structure 
8. RESULTS                                                                                                               84 
 
 
in T. brucei might be eliciting an immune response that cross reacts with some of the 
LacNAc-containing structures available on the glyco-array.  
An unusual (and therefore potentially immunogenic feature) of bloodstream form T. 
brucei poly-LacNAc structures is that the inter-LacNAc linkage is predominantly β1-6 
(as in -6Galβ1-4GlcNAcβ1-6Galβ1-4GlcNAcβ1-) rather than the more common β1-3 
linkage (as in -6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-) found in mammals (Atrih et 
al., 2005).  To test the hypothesis that these unusual β1-6 poly-LacNAc structures of T. 
brucei might be responsible for anti-carbohydrate antibody responses in the infected 
host, we commissioned the chemical synthesis of β1-6 linked poly-LacNAc structures 
by our collaborators, Dr Andrei Nikolaev and Dmitry Yashunsky of the University of 
Dundee and Moscow.  
 
8.2. Poly-LacNAc structures and ELISA development 
Synthetic LacNAc structures (inter-linked by β1-6 glycosidic bonds) and linked to a 
biotin moiety at the reducing terminus by a spacer group were provided with 2, 3 4, and 
5 LacNAc repeats (Figure 8.3). The biotin group was included to facilitate anchoring 
the LacNAc structures, via NeutrAvidinTM, to the ELISA plates. 
 
Unlike in the protein ELISAs described previously, the LacNAc ELISAs did not use the 
two-step biotinylated anti-human IgG followed by HRP-conjugated NeutrAvidin 
detection system because of the biotin present in the synthetic carbohydrate antigens. In 
this case, bound antibodies were detected with HRP conjugated directly to the anti-
human Ig secondary antibodies. The ELISA system was optimised by varying plate 
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antigen concentrations, sera dilutions, secondary antibody dilutions and the 
chemiluminescence substrate solution.   
 
8.3. Immobilised poly-LacNAc ELISA screens with pooled sera 
Pooled T. b. gambiense and T. b. rhodesiense infection and control sera were diluted to 
1:500 in PBS 0.1% BSA and applied in triplicate to NeutrAvidin coated plates which 
had been loaded with the synthetic biotinylated LacNAc repeat structures (3.9.3).  The 
validation set of pooled T. b. gambiense 1st and 2nd stage infection sera showed 
discriminating anti-LacNAc antibody titres with the LacNAc4 and LacNAc5 structures 
compared to control sera (Figure 8.4, A). The pooled T. b. rhodesiense infection sera 
showed no significant reactivity to the synthetic LacNAc structures (Figure 8.4, B). The 
control T. b. rhodesiense sera pool reacted with NeutrAvidin (biotin) plate control 
suggesting there are antibodies directed towards the NeutrAvidin carrier protein.  
Based on these results, we decided to investigate the diagnostic potential of the 
synthetic LacNAc5 structure for T. b. gambiense infection.  
 
8.4. Screening of the LacNAc5 structure with individual T. b. gambiense infection 
and control sera.  
The next step was to screen, in triplicate, the LacNAc5-biotin-NeutrAvidin plates with 
individual patients’ sera (Figure 8.5).  Bound antibodies were detected with HRP 
conjugated to anti-human IgG+IgM+IgA, anti-human IgG or anti-human IgM. The 
ELISA results (mean ± 1 standard deviation) are shown in (Figure 8.5). These results 
suggest that the total (IgG+IgA+IgM) antibody response to the LacNAc5 structure is 
significantly higher in infected patients. Interestingly, the data using specific IgG 
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detection is less impressive whereas the IgM response appears to be more robust. This 
trend can be seen more clearly is the associated box plots shown in Figure 8.5, (D-F).  
As inferred by the box plots the Dunn’s Post Hoc test supports the observation that 1st 
(Q=4.004, P<0.05) and 2nd stage (Q=8.429, P<0.05) sera contain statistically significant 
higher IgM to the lacNAc5 plate compared to the control sera (Table 8.1). There was no 
statistical significance between 1st stage and 2nd stage groups for any antibody response 
to LacNAc5. 
 
Table 8.1: Statistical results for T. b. gambiense LacNAc5 ELISA data.  
Statistical significance determined by Mann-Whitney Rank test or Dunn’s Post-Hoc 
rank test with Q values and Probability (P) values shown, statistical significance is 
shown in bold (P=<0.05). 
 
Antibody 
response to 
LacNAc5 
Mann-Whitney Dunn’s Post-Hoc 
Infection vs. 
Control 
1st stage vs. 2nd 
stage 
1st stage vs. 
Control 
2nd stage vs. 
Control 
IgG, IgA, IgM P=<0.001 Q=0.735 
P>0.05 
Q=3.738 
P<0.05 
Q=7.911 
P<0.05 
IgG P=<0.001 Q=0.475 
P>0.05 
Q=3.727 
P<0.05 
Q=5.726 
P<0.05 
IgM P=<0.001 Q=0.762 
P>0.05 
Q=4.004 
P<0.05 
Q=8.429 
P<0.05 
 
The same ELISA data from Figure 8.5 was also analysed by Receiver-operator 
characteristics (ROC) curve (Figure 8.6) to assess whether infection sera can be 
discriminated based on antibody response to LacNAc5 plates. The IgM response in T. b. 
gambiense infection sera to the LacNAc5 glycan has an area under the ROC curve 
(AUC) of 0.93 whereas the IgG response had an AUC 0.83.  The antibody class 
responses measured here showed infection discrimination between infection and control 
groups (Figure 8.6, B) were statistically significant (P<0.001; Mann-Whitney rank test) 
(Table 8.1).    
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8.5. Re-analysis of the diagnostic potential of LacNAc5 for T. b. rhodesiense 
infection.   
Based on the results with the T. b. gambiense sera, we decided to screen the individual 
T. b. rhodesiense infection and control against the LacNAc5-biotin-NeutrAvidin plates. 
The raw ELISA data show an individual (CR41) who has a high IgG specific anti-
NeutrAvidin response, which is not amplified by anti-human-IgM-HRP secondary 
antibody (Figure 8.7, A-C). The IgM response to lacNAc5 shows an infection-specific 
basis as expressed by the box plots (Figure 8.7, D-F), where only the 2nd stage infected 
group (Q=4.876, P<0.05, Mann-Whitney Rank (MWR) test) was statistically significant 
from control (Table 8.2).  The only other statistical significant difference between 
infection and control sera was the IgG, IgM, IgA ELISA comparing 2nd stage infected 
group (Q=3.575, P<0.05, MWR) with control group.  
 
Table 8.2: Statistical results for T. b. rhodesiense LacNAc5 ELISA data.  
Statistical significance determined by Mann-Whitney Rank test or Dunn’s Post-Hoc 
rank test with Q values and Probability (P) values shown, statistical significance is 
shown in bold (P=<0.05). 
 
Antibody 
response to 
LacNAc5 
Mann-Whitney Dunn’s Post-Hoc 
Infection vs. 
Control 
1st stage vs. 2nd 
stage 
1st stage vs. 
Control 
2nd stage vs. 
Control 
IgG, IgA, IgM P=0.002 Q=1.919 
P>0.05 
Q=0.343 
P>0.05 
Q=3.575 
P<0.05 
IgG P=0.118 Not a statistically significant difference (P=0.279) 
 
IgM P=<0.001 Q=0.891 
P>0.05 
Q=2.193 
P>0.05 
Q=4.876 
P<0.05 
 
The same ELISA data from Figure 8.7 was also analysed by Receiver-operator 
characteristics (ROC) curve (Fig. 8.8) to assess whether infection sera can be 
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discriminated based on antibody response to LacNAc5 plates. The IgM response in T. b. 
rhodesiense infection sera to the LacNAc5 glycan has an area under the ROC curve 
(AUC) of 0.92 whereas the IgG response had an AUC 0.64.  The IgM antibody 
response to LacNAc5 between infection and control groups (Figure 8.8, B) was 
statistically significant (P<0.001; Mann-Whitney rank test) (Table 8.2).    
 
8.6. Summary of findings. Evaluation and comparison of T. b. gambiense and T. b. 
rhodesiense anti-LacNAc-5 antibody response.  
This preliminary data suggest there are specific antibody reactions to the biotinylated 
synthetic LacNAc5 structure found in both T. b. gambiense and T. b. rhodesiense 
infected patients.  The IgM anti-LacNAc5 was found to be higher in infected patients 
compared with controls, and based on these results, LacNAc5 could be considered a 
potential diagnostic antigen for both T. b. gambiense and T. b. rhodesiense infections 
(Table 8.3). 
 
Table 8.3: Sensitivity and specificity scores for both T. b. gambiense (shaded) and T. b. 
rhodesiense (non-shaded) from ELISA experiments detecting different antibody classes 
from the serum (IgG+IgA+IgM, IgG and IgM) to the LacNAc5 plate antigen. For T. b. 
rhodesiense data, R047 patient’s results are not included in statistical analyses.  
 
Sera Antibody 
class 
Cut off > Sensitivity 
(%) 
95% CI Specificity 
(%) 
95% CI 
T. b. 
gambiense 
IgG+IgA+IgM 2628000 86.4 75 to 94 86.2 74.6 to 93.9 
T. b. 
rhodesiense 
IgG+IgA+IgM 1073000 75 53.3 to 90.2 75 50.9 to 91.3 
T. b. 
gambiense 
IgG 1307000 74.6 61.6 to 85 74.1 61 to 84.7 
T. b. 
rhodesiense 
IgG 274807 62.5 40.6 to 81.2 75 50.9 to 91.3 
T. b. 
gambiense 
IgM 7553000 93.2 83.5 to 98.1 86.2 74.6 to 93.9 
T. b. 
rhodesiense 
IgM 3578000 87.5 67.6 to 97.3 80 56.3 to 94.3 
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In comparison with the most promising protein antigen candidate for T. b. rhodesiense 
infections, rISG64-3, which had sensitivity and specificity scores of 92 % and 85 %, the 
LacNAc5 antigen (IgM) scored 87.5 % and 80 %, respectively.  Therefore further 
optimisation and validation needs to be carried out to fully assess the diagnostic 
potential for LacNAc5 antigen. Further studies would include quantifying total IgM 
concentration in all sera, to see if these results are due to a higher overall IgM rather 
than specific anti-LacNAc5 antibodies. 
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9. Discussion  
The overall goal of this project was to develop a field-based diagnostic assay (lateral 
flow test) that could replace the CATT screening tool. The specific aims of this project 
were, i) to identify new potential diagnostic candidates for HAT, ii) to investigate if the 
candidates could be solubly expressed and purified, and, finally iii) to assess their 
diagnostic potential with patients sera. We took an un-biased approach to identify 
potential diagnostic biomarkers, and identified several cell surface glycoproteins such as 
the ISGs, ESAG 6 and 7, ESAG 2 and ESAG 11. A selection of these were then cloned, 
recombinantly expressed and purified from E. coli. These expressed proteins were 
assessed by ELISA with serum from T. b. gambiense and T. b. rhodesiense infected and 
control individuals and rISG65-1 and sVSG117 were selected to be developed into 
lateral flow assays for re-testing with randomised sera.  Based on this initial assessment 
the ELISA and lateral flow prototypes match the CATT sensitivity and surpass the 
specificity scores (Table 9.1)(Truc et al., 2002a). 
Table 9.1: Sensitivity and specificity of CATT, rISG65-1 and sVSG117 ELISAs and 
lateral flow scores. CATT(1) values from (Truc et al., 2002a). 
 
Test/Antigen Sensitivity (95 % CI) Specificity (95% CI) 
CATT 87-98 %1 93-95 %1 
rISG65 ELISA 97 % (88 to 100%) 93 % (83.5 to 98%) 
sVSG117 ELISA 100 % (93.9 to 100%) 100 % (93.9 to 100%) 
rISG65 lateral flow 
(visual score) 
88 % (73 to 96%) 93 % (79.6 to 98%) 
sVSG117 lateral flow 
(visual score) 
100 % (91 to 100%) 100 % (91 to 100%) 
rISG65 lateral flow 
(Camag score) 
100 % (91 to 100%) 93 % (79.6 to 98%) 
sVSG117 lateral flow 
(Camag score) 
97.5 % (86.8 to 99.9) 97.5 % (86.8 to 99.9) 
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9.1. Immunoprecipitation and the selection criteria 
Identification of new potential diagnostic markers was necessary due to limited options 
of potential diagnostic markers that could be used in an lateral flow assay (Manful et al., 
2010, van Nieuwenhove et al., 2011, Radwanska et al., 2000). In our study potential 
diagnostic biomarkers were identified by proteomic analysis of proteins that adsorbed to 
IgG columns derived from either infected or uninfected pools of patient sera. Many of 
the proteins identified were common to both infected and uninfected control elutions. 
Some of the antigens found in both samples might be specifically recognised by normal 
human IgG through, for example, cross-reacting antigens from other infections, while 
others might bind to IgG-Sepharose non-specifically.  Heat Shock Protein 70 (HSP70) 
was identified by both T. b. gambiense infected and control patients’ IgG with high 
MASCOT scores of 2325 and 2194, respectively, suggesting it is a poor diagnostic 
candidate (Appendix Table A1 and A2). Heat shock protein (HSP) 70 has been 
proposed to be potential diagnostic candidate  in cattle infections (Bossard et al., 2010) 
and for T. b. rhodesiense infections in man (Manful et al., 2010), although both studies 
acknowledged limitations in using HSP70 exclusively.  Soluble VSG117 was identified 
by both T. b. gambiense and control patients IgG with MASCOT scores of 2271 and 
859, suggesting limited potential as a diagnostic marker (Appendix Table A1 and A2). 
However, the ELISA and lateral flow data show this is not the case. A potential 
explanation for the presence of sVSG117 in the control elution may be due to the high 
abundance of VSG which may have non-specifically bound to the control IgG column 
and was not washed away before elution. Another explanation may be that the 
antibodies may have recognised the CRD rather than the protein sequence. VSG117 has 
been found to be expressed by other trypanosome species, such as, T. evansi (Jia et al., 
9. DISCUSSION                                                                                                           92 
 
 
2012) which infects camels, horses, cattle and buffaloes, so there may be potential for 
the T. b. brucei sVSG117 to be utilised for diagnosis in these infections.   
While our approach succeeded in the identification of novel biomarkers there were 
limitations. A major limit was caused by the decision to use only four patients’ sera in 
the pools for the infection and non-infection IgG columns. Ideally a pool of many more 
patients’ IgG would be preferable as this may allow for more biomarkers. However this 
was avoided due to the uncertain provenance of the serum used. Alternatively, 
immunoprecipitation with each individual patient’s IgG could have been done and the 
proteins identified for each could allow for common antigens to be identified, however 
this would be very resource intensive and the amount of sera available was limited. 
Another limitation is the fact that T. b. brucei lysate was used rather than the infection 
relevant strains T. b. gambiense and T. b. rhodesiense, which, at the time was not 
available for use as we did not have clonal isolates. Use of these lysates would have 
been more appropriate and potentially may have allowed for additional strain specific 
biomarkers.  
 
9.2. Recombinant or native biomarkers? 
Recombinant expression is an efficient method for obtaining large quantities of 
diagnostic antigen, providing the antigen can be solubly expressed and purified.  The 
recombinant proteins were selected based on their sequence similarity to the ISG and 
GRESAG4 sequences identified in the immunoprecipitation and therefore will contain 
antibody epitopes present during an infection. However, there were difficulties in the 
expression and purification of ISG75 and GRESAG4. The problems with ISG75 are 
likely to be due to the multiple disulphide bonds, which need to be correctly aligned for 
correct folding (Ziegelbauer et al., 1992).  In the trypanosome, ISG proteins are 
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translated in the Endoplasmic reticulum, which is a highly oxidative environment 
containing chaperone and other proteins which facilitate the correct tertiary structure of 
proteins containing disulphide bonds and remove incorrectly folded proteins. Future 
experiments would include utilising bacterial expression systems that target 
recombinant proteins into the periplasmic space, this could be useful as recombinant 
proteins are processed through the secretory system (Arredondo and Georgiou, 2011). 
This strategy could also be employed for recombinant GRESAG proteins.  Re-
assessment of ISG75 and GRESAG proteins should be carried out once expression and 
purification conditions have been further optimised, as their poor performance in 
ELISA may be due to incorrect folding of the proteins. 
 
Recombinant and synthetic antigens, such as rISG65-1 and biotinylated-LacNAc5 (IgM) 
antigens have very good diagnostic potential as shown by the ELISA data. Analysis of 
this ELISA data by ROC curve showed AUC of 0.99 for rISG65-1 and AUC of 0.96 for 
LacNAc5 (IgM) indicating discrimination between T. b. gambiense infection and 
control sera. For T. b. rhodesiense individuals the analysis of ELISA data for rISG65-1 
gave an AUC of 0.84 and LacNAc5 (IgM) antigen an AUC of 0.92, suggesting these 
antigens are able to discriminate between infection and control sera.  The native 
sVSG117 had greater diagnostic potential for the T. b. gambiense infection (defined by 
ELISA) with sera showing an area under ROC curve score of 1.  The sVSGs can be 
relatively easily purified from total T. brucei lysate and there is no concern about 
contaminating E. coli proteins and correct folding of the protein. In addition, the native 
sVSG contains N-linked glycan structures and the CRD, which can be the sites of many 
antibody epitopes, in particular at the interface between glycan and peptide sequence 
(Galanina et al., 2003).  There are many examples of the use of either recombinant and 
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native antigens, to which each have limitations (Akyar et al., 2010, Abdo et al., 2010, 
Martínez-Sernández et al., 2011, El-Moamly et al., 2011, Widmer et al., 1999), 
however a test that combines native and recombinant antigens may improve diagnostic 
outcomes (Busse et al., 2008).    
 
9.3. Validation for diagnostic assays  
As a validation assay the ELISA worked very well. The sensitivity of the ELISA 
matched the sensitivity of the lateral flow assays (Table 9.1). ELISA does have 
limitations, as it is limited by which class of antibody amplified, as shown in the 
LacNAc ELISA, where patients had more IgM anti-LacNAc antibodies than IgG. A 
new validation approach is being investigated is not limited by which antibody class. 
This relies on the AlphaLISA technology where antigens, coupled to donor and acceptor 
beads, are brought into close proximity with each other by any antibodies in the sera, 
the beads are then excited by a specific wavelength where emission signals allows for 
quantification (Bielefeld-Sevigny, 2009, Modi et al., 2011). Alternatively, validation of 
prospective diagnostic antigen should be assessed by lateral flow principles, for 
instance, using dot blots with colloidal gold conjugated antigen to amplify the signal, 
rather than conventional secondary and tertiary antibody amplification. This could 
better assess the potential of new antigens by not taking account of which antibodies are 
responsible in the first assessment. 
 
The prototype lateral flow tests in their present state are not suitable for use in the field 
as they require further optimisation of the test antigen, the addition of a blood pad, and 
rigorous validation against a greater number of sera. Further research is also required to 
measure the half-life of antibodies in patients after they have been treated for HAT, as 
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persistent antibodies may lead to false positives. Lateral flow tests, whilst having 
limitations would potentially be more suitable for use in the field because of their 
stability and the fact that they can be used by non-specialists (Bandla et al., 2011). In 
addition the lateral flow format is versatile, in that the HAT test lines could be could be 
incorporated into a test which also screens for other diseases such as malaria, which 
often co-exists in HAT endemic areas (Bell and Perkins, 2008). 
 
9.4. Sera 
This work is only as good as the resources available and the WHO HAT sera were well 
characterised. Further validation of the antigens with sera from non-endemic regions 
may be necessary, such as the well characterised sera from the TB sera bank  
(Nathanson et al., 2010) and other organisations holding patient’s sera.  The false 
positives observed in the lateral flow studies may be due to cross-reacting antibodies, a 
previous infection or an undiagnosed self-curing infection (Jamonneau et al., 2012).  It 
has been described that antibodies can persist up to 3 years post cure, however it is not 
known which class of antibodies persist or which antigens they recognise (Paquet et al., 
1992). A longitudinal study should be carried out to gain a greater insight into this and 
how it could affect the diagnostic potential of any future lateral flow test relying on 
antibodies. Also the lateral flow assay and other recombinant antigens described here, 
should be investigated with patients who tested positive with the Tryanolysis Test (TL) 
(Jamonneau et al., 2010). This test which is similar to the CATT and uses crude 
preparations of total trypanosome suspensions which may reveal any cross-reactive 
antigens. In addition, a longitudinal study may allow for the identification of antigens 
that are recognised by active infections and those antigens that induce longer lasting 
immunological memory (Jamonneau et al., 2012, Ilboudo et al., 2011) .  
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Due to the limitations of parasite identification in infected blood, other serodiagnostic 
methods are required, with each test having limitations and advantages. Antibody based 
techniques are very sensitive and specific, however the current field screening tool 
(CATT) lacks assay sensitivity, compared to ELISAs. There is also the issue of 
antibody detection that is not suitable for checking efficacy of treatments due to 
persistent circulating anti-trypanosome antibodies (Paquet et al., 1992, Radwanska, 
2010). On the other hand, many methods to detect parasite derived products, such as 
PCR based methods and centrifuge methods, are not suitable for the field, due to the 
requirement of centrifuges, PCR cyclers, electricity for storage of reagents and other lab 
based equipment and trained personnel (Deborggraeve and Büscher, 2010).   
There were differences in the infection profiles between the trypanosome sub species, 
the antibody responses to different biomarkers depending on the infection species. This 
may be attributed to the differing nature of the infections; T. b. rhodesiense infection 
has a faster progression which may not allow enough time for antibody production in 
the host. Whereas T. b. gambiense infected patients may have had months if not years of 
exposure to the parasite and this could in turn lead to a greater diversity of antibodies 
present in their sera. 
 
9.5. Staging 
The staging of the disease is currently problematic and is still necessary until a new 
drug that is safe and active in both stages of the disease, in that instance staging will not 
be so crucial (Bisser and Courtioux, 2012). However it is not known when a new drug 
will be discovered so diagnostic tests that can reliably identify infected patients are 
needed (Matovu et al., 2012). There are precedents in the literature for combining 
diagnosis of innate and adaptive immune response to infections, e.g. in mycobacterial 
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diseases where IL-10 levels and anti-phenolic glycolipid (PGL-I) antibodies can be 
simultaneously detected (Corstjens et al., 2011). In HAT this may be possible for 
markers such as matrix metalloproteinase-9, CKCL10 or anti-galactocerebroside 
antibodies (Courtioux et al., 2005, Hainard et al., 2009, Hainard et al., 2011), however 
these all still require CSF sampling.  
 
9.6. Summary 
An ideal scenario would be to have complementary diagnostic tests, drawing on the 
strengths of each approach. The use of a more sensitive antibody screening tool to 
identify suspected patients, followed by parasite confirmation either with microscopy, 
LAMP or PCR methods maybe possible. This strategy could also be used when 
checking for the efficacy of treatment.  The CATT screening tool needs to be updated 
and lateral flow tests could provide a new platform for the diagnosis of HAT. Hopefully 
the work carried out here can help further the progress of developing a field compatible 
diagnostic tool. Ultimately, this tool would be used to identify patients infected with 
Trypanosome infection enabling them to be treated, thus saving and improving the lives 
of those affected by HAT.    
 
 
 
 
 
 
10. APPENDIX                                                                                                            98 
 
 
Appendix 1: Detailed results from the second immunoprecipitation and proteomic 
experiments described in Chapter 4. 
 
Table A1: T. b. brucei proteins identified in the infection-IgG elution.  Proteins 
ordered in ascending MASCOT score. 
Description Identifier MW MASCOT 
score 
number of 
peptides 
matched 
75kDa Invariant surface glycoprotein Uniref100_Q26714 58661 2584 97 
ALD fructose-bisphosphate aldolase, 
glycosomal 
Tb10.70.1370 41045 2490 81 
HK1 hexokinase Tb10.70.5820 51262 2346 62 
heat shock protein 70 Tb11.01.3110 75320 2325 72 
Variant surface glycoprotein MITAT 
1.4A precursor 
UniRef100_P02896 56282 2271 88 
glucose-regulated protein 78 Tb11.02.5450 71391 1750 50 
Receptor-type adenylate cyclase 
GRESAG 4 
Tb927.7.7530 137920 1456 67 
ESAG 7 Tb427 telo10 v1 145 38433 1152 31 
65kDa Invariant surface glycoprotein Uniref100_Q26712 48192 1098 39 
gPGK phosphoglycerate kinase Tb927.1.700 47558 1026 37 
Phosphoglycerate kinase, glycosomal uniref100_P07378 47431 997 35 
Glycosomal membrane protein uniref100_O60944 24210 936 29 
chaperone protein DnaJ Tb927.2.5160 44786 832 23 
heat shock protein 83 Tb10.26.1080 80712 821 26 
Hypothetical protein Tb427_telo10_v1_145 38889 811 28 
GAPDH glyceraldehyde 3-phosphate 
dehydrogenase, glycosomal 
Tb06.26G9.1050 43841 772 23 
hypothetical protein Tb927.4.1300 41988 765 26 
TEF1 elongation factor 1-alpha Tb10.70.5670 49474 754 33 
Hypothetical protein Tb427_telo56_all_533 38611 739 19 
hypothetical protein Tb09.160.5530 37993 737 19 
Hypothetical protein Tb427_telo15_all_453 39034 729 16 
AK arginine kinase Tb09.160.4570 41571 708 27 
RNA-binding protein, putative Tb927.8.6440 20529 664 16 
ATP synthase F1, beta subunit Tb927.3.1380 55741 645 16 
TIM triosephosphate isomerase Tb11.02.3210 26973 640 23 
2-oxoglutarate dehydrogenase, E2 
component, dihydrolipoamide 
succinyltransferase 
Tb11.01.3550 41516 601 21 
64 kDa invariant surface glycoprotein Tb927.5.1410 46867 582 23 
gim5B Gim5B protein; glycosomal 
membrane protein 
Tb09.211.2740 26529 524 23 
DRBD3 RNA-binding protein Tb09.211.0560 36961 519 19 
glucose-regulated protein 78/luminal 
binding protein 1 (BiP) 
Tb11.02.5450 71505 519 15 
Polyubiquitin Tb11.01.1680 76556 510 10 
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kinetoplastid membrane protein KMP-11 Tb09.211.4511 11069 489 23 
protein disulfide isomerase Tb927.7.1300 41913 445 16 
dynein light chain Tb11.50.0007 10422 422 9 
alpha tubulin Tb927.1.2340 50383 418 17 
AOX; TAO alternative oxidase Tb10.6k15.3640 37738 408 23 
(H+)-ATPase G subunit Tb927.8.2310 12741 393 9 
hypothetical protein Tb927.6.3020 32198 368 8 
RPS12 40S ribosomal protein S12 Tb10.6k15.2050 16279 319 8 
Hypothetical protein Tb11.02.0010/ 
uniref100_Q386R9 
24706 301 7 
hypothetical protein Tb09.160.5200 32552 288 10 
14-3-3-like protein Tb11.01.1290 30291 282 10 
tGLP1 Golgi/lysosome glycoprotein 1 Tb927.8.1870 67555 274 8 
variant surface glycoprotein (VSG)-
related 
Tb11.02.1566 40752 270 7 
Hypothetical protein Tb10.61.2850/ 
Uniref100_Q388J6 
50899 270 9 
Hypothetical protein Tb10.70.1130/ 
Uniref100_Q38B23 
48342 269 6 
ESAG6 and hypothetical protein Uniref100_Q8WPU1 44221 256 10 
Hypothetical protein Tb427_telo51 
(&59)_v2_533 
44959 256 10 
hypoxanthine-guanine 
phosphoribosyltransferase 
Tb10.70.6660 26515 248 8 
LA La protein; RNA-binding protein Tb10.70.5360 37636 243 8 
Hypothetical protein Tb427_telo15 
(&4)_all_528(&157) 
45097 241 9 
Hypothetical protein Tb427_telo10_v1_217 45096 241 14 
expression site-associated gene 2 
(ESAG2) protein 
Tb927.1.4890 53686 235 7 
PEX14 peroxin 14 Tb10.100.0130 39970 226 8 
Flagellar calcium-binding protein TB-17 UniRef100_P17882 25477 220 6 
Vacuolar ATP synthase subunit B Tb11.01.3560 55927 220 5 
hypothetical protein Tb927.6.4440 37695 218 6 
Hypothetical protein Tb427_telo_v1_217 45096 214 10 
Hsc70-interacting protein (Hip), Tb927.3.5340 42173 211 5 
Hypothetical protein Tb11.01.0210/ 
Uniref100_Q386P9 
51028 209 3 
Hypothetical protein Tb927.7.2120 46341 202 6 
60S ribosomal protein L18a Tb10.70.3510 21119 198 6 
Hypothetical protein Tb927.6.4440/ 
uniref100_Q587B0 
37923 198 6 
hypothetical protein Tb927.7.180 49781 197 5 
GTP binding protein Tb927.2.5060 44664 185 6 
PRS phosphoribosylpyrophosphate 
synthetase, 
Tb10.6k15.0970 40452 185 7 
histone H4 Tb927.5.4170 11135 184 4 
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proteasome alpha 3 subunit   179  
elongation factor 1 gamma Tb11.01.4660 46274 178 6 
adenylosuccinate synthetase Tb11.02.1120 67317 167 8 
TbL18LP 60S ribosomal protein L18   164  
hypothetical protein Tb927.4.2030 22691 159 7 
ESAG11 Tb927.1.4900/ 
Tb42_telo126_all_1147/ 
Uniref100_Q4GY70 
32032 156 5 
PRS phosphoribosylpyrophosphate 
synthetase, 
Tb927.5.2960 42342 156 4 
Hypothetical protein Tb427_telo10_v1_217 45096 156 6 
ESAG2 Tb11.01.6230 56132 150 5 
eukaryotic translation initiation factor 5, 
putative 
Tb10.70.4880 43431 144 2 
hypothetical protein Tb11.02.2030 12750 143 3 
Hypothetical protein Tb927.6.4180 16317 140 2 
HSP60 chaperonin Tb10.70.0430 59751 139 4 
TRYP2 tryparedoxin peroxidase   136  
calpain-like protein fragment Tb927.1.2260 14021 135 4 
thioredoxin Tb927.4.2450 44748 132 4 
hypothetical protein Tb11.01.7070 23157 132 3 
NDPK nucleoside diphosphate kinase   130  
LPG3/heat shock protein 90/glucose 
regulated protein 94 
Tb927.3.3580 87712 128 3 
nucleoside hydrolase Tb927.7.4570 39366 121 4 
TCP-1-theta t-complex protein 1 Tb10.6k15.2330 58501 118 2 
hypothetical protein Tb927.3.1300 46058 115 2 
Hypothetical protein Tb927.6.3020 32369 115 3 
Glycerol kinase Tb09.211.3540 57041 113 6 
hypothetical protein Tb927.4.2030 22691 111 2 
NHP2 ribosomal protein S6 Tb09.160.3670 13563 109 2 
Hypothetical protein Tb927.6.2860 49790 109 3 
lysosomal/endosomal membrane protein 
p67 
Tb927.5.1810 72686 104 2 
Hypothetical protein Tb427_telo15_all_954 428587 102 4 
PYK1 pyruvate kinase 1 Tb10.61.2680 39170 100 4 
TDP1 high mobility group protein Tb927.3.3490 30847 97 4 
I/6 autoantigen Tb927.7.3440 27261 95 4 
elongation factor 2 Tb10.70.2660 95300 94 4 
Hypothetical protein Tb927.4.2740 16317 94 3 
phospholipase A1   93  
beta tubulin Tb927.1.2330 50413 90 3 
Gp63-3 surface protease homology Uniref100_Q4FKH2 70254 89 2 
acidic ribosomal protein   88  
Hypothetical protein Tb927.6.4140/ 13229 87 3 
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uniref100_Q586B2 
dynein-associated protein Tb09.211.4920 11123 85 2 
Hypothetical protein Tb927.3.1300 46343 82 2 
TbP34 RNA-binding protein   81  
metalloprotease, putative; cell division 
protein FtsH homologue 
Tb11.01.6360 74429 80 2 
acyl carrier protein, mitochondrial 
precursor 
Tb927.3.860 16520 78 2 
Hypothetical protein Tb10.6k15.3950/ 
uniref100_Q38AS5 
35254 76 3 
hypothetical protein Tb927.7.2190 29224 71 2 
RBP29 RNA binding protein Tb10.61.3200 41052 70 5 
Hypothetical protein Tb927.7.2570 52912 70 2 
gk glycerol kinase, glycosomal Tb09.211.3540 56299 67 1 
epsin Tb11.50.0006 55460 66 2 
RuvB-like DNA helicase Tb927.4.1270 50049 62 2 
hypothetical protein Tb11.01.4280 44945 60 2 
Hypothetical protein Tb927.4.2030/ 
uniref100_Q583I9 
22691 60 2 
flagellum-adhesion glycoprotein Tb927.8.4060 64947 59 1 
BS2 protein disulphide isomerase Tb10.6k15.2290 55887 57 1 
Hypothetical protein Tb11.02.4300/ 
Uniref100_Q385C5 
48868 56 2 
Hypothetical protein Tb11.02.1910/ 
uniref100_Q385Y1 
36953 56 2 
Hypothetical protein Tb927.5.2100 49921 52 2 
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Table A2: T. b. brucei proteins identified in the non-infection-IgG elution.   Proteins 
ordered in ascending MASCOT score. Experiment described in Chapter 4. 
 
Description Identifier Mol wt. MASCOT 
score 
number of 
peptides 
matched 
Hexokinase UniRef100_Q95PL2 51834 5179 134 
Heat shock 70 kDa protein 4 UniRef100_P11145 71676 2194 73 
ALD fructose-bisphosphate 
aldolase, glycosomal 
Tb10.70.1370 41558 1866 54 
Variant surface glycoprotein MITat 
1.8 
UniRef100_Q58NS6 50790 1602 49 
TEF1 elongation factor 1-alpha Tb10.70.5670 49474 1430 44 
Glycosomal membrane protein uniref100_O60944 24210 1385 42 
glucose-regulated protein 78 Tb11.02.5450 71505 1353 44 
Pyruvate kinase 1 UniRef100_P30615 55287 1057 34 
chaperone protein DnaJ Tb927.2.5160 45356 1026 26 
gPGK phosphoglycerate kinase Tb927.1.700 47558 990 36 
Phosphoglycerate kinase uniref100_P07378 47431 932 33 
Heat shock protein 83 Tb10.26.1080 81169 878 34 
Variant surface glycoprotein 
MITAT 1.4A precursor 
UniRef100_P02896 57081 859 31 
2-oxoglutarate dehydrogenase  Tb11.01.3550 41516 852 27 
gim5A protein Tb09.211.2730 26790 821 25 
hypothetical protein Tb09.160.5530 38335 797 23 
vacuolar ATP synthase subunit B Tb11.01.3560 55927 745 22 
TIM triosephosphate isomerase Tb11.02.3210 26973 660 24 
AK arginine kinase Tb09.160.4590 40457 659 23 
GAPDH Tb927.6.4280 44241 653 32 
glycerol-3-phosphate dehydrogenase Tb927.8.3530 38408 643 23 
Arginine kinase UniRef100_Q9U420 40375 638 23 
alpha tubulin Tb927.1.2340 50383 623 16 
protein disulfide isomerase Tb927.7.1300 42256 594 22 
14-3-3-like protein Tb11.01.1290 30462 553 17 
gk glycerol kinase, glycosomal Tb09.211.3570 57117 516 18 
elongation factor 1 gamma Tb11.01.4660 46730 506 17 
ATP synthase beta chain, 
mitochondrial precursor 
Tb927.3.1380 55969 503 16 
hypothetical protein Tb927.7.180 50408 490 13 
variant surface glycoprotein (VSG)-
related 
Tb11.02.1566 41493 472 15 
ATP synthase Tb11.01.1190 24944 450 16 
(H+)-ATPase G subunit Tb927.8.2310 12798 428 9 
dynein light chain Tb11.50.0007 10479 400 10 
DRBD3 RNA-binding protein Tb09.211.0560 37018 362 13 
S-adenosylhomocysteine hydrolase Tb11.01.1350 49101 360 12 
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cytosolic malate dehydrogenase Tb11.01.3040 35528 349 12 
Elongation factor Tb10.70.2660 95300 334 14 
V-type ATPase, A subunit Tb927.4.1080 68219 330 12 
hypothetical protein Tb927.4.1300 42444 330 10 
HK2 hexokinase Tb10.70.5800 51630 329 12 
enolase Tb10.70.4740 47133 324 11 
hypothetical protein Tb09.160.5200 32837 323 12 
Hypothetical protein Tb11.02.0010/ 
Uniref100_Q386R9 
24706 318 8 
aspartyl aminopeptidase, putative; 
metallo-peptidase, Clan MH, Family 
M20 
Tb927.3.3410 49809 317 9 
Thioredoxin Tb927.4.2450 44748 314 13 
TAO alturnative oxidase Tb10.6k15.3640 37738 309 17 
Hsc70-interacting protein  Tb927.3.5340 42173 309 6 
kinetoplastid membrane protein 
KMP-11 
Tb09.211.4511 11069 301 11 
NHP2 ribosomal protein S6 Tb09.160.3670 13620 300 6 
hypothetical protein Tb927.6.4440 37923 290 6 
NRBD2 Tb11.01.5590 30256 268 8 
proliferative cell nuclear antign Tb09.160.3710 32750 267 9 
hypothetical protein Tb927.2.4090 29534 259 5 
NDPK Tb11.01.7800 16904 243 9 
hypoxanine-guanine 
phosphoribosyltransferase 
Tb10.70.6660 26515 228 8 
ribosomal protein S5 Tb11.02.4170 21487 225 5 
hypothetical protein Tb927.5.1780 49188 225 6 
stress-induced protein sti1 Tb927.5.2940 62915 223 7 
Protease alpha 3 subunit Tb927.7.4420 32362 223 9 
ADP-ribosylation factor-like protein 
3A 
Tb927.3.3450 20096 220 5 
calpain-like protein fragment Tb927.1.2260 14192 218 6 
RBP29 RNA-binding protein Tb10.61.3200 41052 216 8 
RuvB-like DNA helicase Tb927.4.2000 52805 216 9 
beta tubulin Tb927.1.2330 50413 215 8 
RPS12 40S ribosomal protein Tb10.6k15.2050 16279 212 7 
protein disulphide isomerase Tb927.7.1300 42256 199 8 
Proteasome subunit alpha type 1 UniRef100_O96788 29431 195 7 
eukaryotic translation initiation 
factor 5 
Tb10.70.4880 43431 194 5 
hypothetical protein Tb11.02.4120 27640 194 5 
reticulon domain protein Tb927.6.3840 21285 190 9 
Hypothetical protein Tb10.61.2850 50899 187 6 
LPG3 Tb927.3.3580 87712 184 5 
hypothetical protein Tb10.26.0680 14433 183 7 
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hypothetical protein Tb927.4.2030 22691 183 7 
60S acidic ribosomal subunit protein Tb11.46.0002 34891 179 5 
RNA binding protein Tb927.8.6440 20529 178 4 
serine/threonine protein phosphatase Tb927.6.640 79913 176 5 
tGLP1 Golgi/lysosome glycoprotein 
1 
Tb927.8.1870 68353 176 5 
Tb427 telo10 v1 145 Tb427 telo10 v1 145 38889 175 3 
hypothetical protein Tb927.6.2860 49790 175 4 
acidic phosphatase Tb927.5.610 48166 166 4 
short chain dehydrogenase Tb927.5.1210 34083 163 7 
dynein-associated protein Tb09.211.4920 11237 162 6 
GTP binding protein  Tb927.2.5060 44664 159 6 
MCA4 metacaspase  Tb10.70.5250 39628 157 5 
hypothetical protein Tb11.02.2890 26237 156 4 
nucleoside hydrolase Tb927.7.4570 39708 155 5 
ATP synthase alpha chain Tb927.7.7420 63862 155 5 
hypothetical protein Tb10.6k15.3240 25630 152 4 
40S ribosomal protein S4 Tb11.02.1085 30739 150 10 
translation elongation factor 1-beta Tb10.70.1100 21945 145 6 
TB-24 flagellar calcium-binding 
protein 
Tb927.8.5440 24580 144 5 
adenylosuccinate synthetase Tb11.02.1120 67317 138 7 
small nuclear ribonucleoprotein 
SmD1 
Tb927.2.4540 12324 137 5 
acyl carrier protein, mitochondrial 
precursor 
Tb927.3.860 16577 137 4 
hypothetical protein Tb10.61.3130 75312 135 4 
nascent polypeptide associated 
complex alpha subunit 
Tb11.01.1465 11456 134 4 
calreticulin Tb927.4.5010 45242 134 3 
TRYP2 tryparedoxin peroxidase Tb927.8.1990 25786 134 4 
HGPRT  Tb10.70.6650 23573 133 5 
guanine deaminase Tb927.5.4560 55875 132 2 
gnD 6-phosphogluconate 
dehydrogenase, decarboxylating 
Tb09.211.3180 52532 131 5 
HSP60 Tb10.70.0430 59751 130 4 
profilin Tb11.01.5350 16340 130 3 
adenylosuccinate synthetase Tb11.02.1120 67317 130 5 
hypothetical protein Tb11.39.0004 45720 130 3 
Hypothetical protein Tb927.4.2740/ 
uniref100_Q583A1 
16317 128 5 
LA La protein; RNA-binding 
protein 
Tb10.70.5360 37693 127 6 
hypothetical protein Tb927.1.2970 27339 127 4 
hypothetical protein Tb927.7.4120 52218 126 3 
phospholipase A1 Tb927.1.4830 32782 124 3 
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hypothetical protein Tb927.7.2190 29338 124 3 
Hypothetical protein Tb927.4.2530/ 
uniref100_Q584D4 
16881 121 3 
hypothetical protein Tb11.01.1980 12901 120 3 
hypothetical protein Tb11.01.7740 33169 119 4 
Hypothetical protein Tb09.160.4440 30870 118 5 
VAMP Tb927.5.3560 24672 111 2 
hypothetical protein Tb927.7.4260 29346 110 2 
tyrosyl-tRNA synthetase Tb927.7.2400 46225 109 3 
proteasome regulatory non-ATP-ase 
subunit 
Tb11.01.6030 31375 107 4 
Sm-D2 small nuclear 
ribonucleoprotein SmD2 
Tb927.2.5850 12568 106 2 
HSP10 10 kDa heat shock protein Tb927.7.1320 10664 106 1 
PRS phosphoribosylpyrophosphate 
synthetase 
Tb10.6k15.0970 41193 104 3 
Hypothetical protein Tb09.211.0410/ 
uniref100_Q38EB9 
32407 103 2 
Hypothetical protein Tb927.3.1680/ 
uniref100_Q57ZE3 
35454 102 3 
Tb427 telo10 v1 660 Tb427 telo10 v1 660 61483 101 4 
hypothetical protein Tb11.02.4300 48868 101 3 
histone H4 Tb927.5.4170 11135 100 3 
hypothetical protein Tb927.5.2100 49921 100 2 
hypothetical protein Tb10.6k15.0255 11373 98 2 
hypothetical protein Tb927.1.5000 30497 97 3 
hypothetical protein Tb11.01.6715 111121 95 2 
autoantigen uniref100_Q26768 27975 93 5 
Hypothetical protein Tb10.70.1130 48342 92 2 
Hypothetical protein Tb927.8.1170/ 
uniref100_Q57VN5 
36796 90 5 
metalloprotease Tb11.01.6360 74711 87 4 
adenine phosphoribosyltransferase Tb927.7.1780 26185 85 3 
nucleosome assembly protein-like 
protein 
Tb09.160.4240 47784 84 3 
hypothetical protein Tb07.22O10.680 52912 84 2 
TDP1 high mobility group protein Tb927.3.3490 30847 83 4 
glycosomal phosphoenolpyruvate 
carboxykinase; glycosomal 
Tb927.2.4210 58927 82 3 
TCTP Tb927.8.6750 19367 81 2 
succinyl-CoA ligase Tb10.6k15.3250 55571 80 3 
GBP21 mitochondrial RNA binding 
protein1 
Tb11.55.0009 23353 79 2 
hypothetical protein Tb927.4.1610 39892 79 1 
TbP34 RNA-binding protein Tb11.01.5570 28759 78 2 
PEX11 glycosonal membrane 
protein 
Tb11.01.3370 24240 73 4 
Hypothetical protein Tb10.6k15.3950/ 35254 70 3 
10. APPENDIX                                                                                                            106 
 
 
uniref100_Q38AS5 
PEX14 peroxin 14 Tb10.100.0130 39970 69 2 
hypothetical protein Tb927.3.5540 58722 68 1 
UBA2 ubiquitin-activating enzyme 
E1 
Tb09.211.3610 136223 67 1 
ACS3 fatty acyl CoA synthetase 3 Tb09.160.2810 78603 65 3 
zinc metallopeptidase Tb10.05.0230 62911 65 2 
protein kinase Tb10.70.2070 49824 65 2 
hypothetical protein Tb09.211.3110 44770 64 2 
Hypothetical protein Tb927.8.2070/ 
uniref100_Q57XG1 
22184 64 3 
asparate aminotransferase Tb10.70.3710 44930 62 2 
RPN5 proteasome regulatory non-
ATP-ase subunit 5 
Tb10.70.6360 55375 60 2 
casein kinase 2 Tb11.01.2590 33898 58 2 
Hypothetical protein Tb09.211.1150/ 
uniref100_Q38E40 
20679 58 2 
TbNT3 adenosine transporter 2 Tb927.2.6200 51584 56 2 
GPI transamidase component TTA1 uniref100_Q7YTW4 42139 56 2 
Hypothetical protein Tb11.01.7070/ 
Uniref100_Q38IP3 
23157 55 1 
asparaginyl-tRNA synthetase Tb927.4.2310 85386 54 1 
coatomer epsilon subunit Tb11.01.6530 347858 51 2 
Hypothetical protein Tb11.01.5680 51983 51 2 
Hypothetical protein Tb11.01.7200/ 
uniref100_Q381M9 
52925 51 2 
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Appendix 2: Bioclinical data for the patients used in the validation sera set, data 
and samples from the WHO HAT specimen bank. 
 
Table A3: General and clinical information of patients infected with T. b. 
gambiense. Shaded ID codes represent the 1 st stage patients. Table shows where 
patients were diagnosed, either at a hospital (H) or by mobile team (MT), if the patient 
were in an at-risk area (Yes) or not a high risk area (No) or unknown (UN). Patient’s 
sex and age were recorded. The patient’s general appearance at diagnosis (1, not ill; 2, 
mildly ill; 3, moderately ill; 4, gravely ill) and the duration of their main symptom (see 
table A7 for details of the bioclinical information) are shown. Females that were 
pregnant are shown as ‘Female’. 
 
ID Hospital 
(H) or 
Mobile 
Team 
(MT) 
Risk area? Male or 
Female 
Age General 
appearance 
Signs and 
symptoms 
Duration 
of main 
symptom 
(weeks) 
4-01 MT Yes Female 13 2 0  
4-02 MT No Male 59 2 0 1 
4-06 MT Yes Female 20 2 3  
5-03 MT UN Female 33 3 5  
5-04 MT Yes Female 48 2 6  
5-05 MT Yes Female 46 2 6  
1-13 MT Yes Male 30 1 0 4 
1-18 MT Yes Male 20 3 0 40 
1-20 MT Yes Male 18 2 7 2 
1-21 MT Yes Male 20 3 0 50 
        
2-21 H Yes Male 23 3 0 72 
2-24 H Yes Male 28 3 0 48 
2-26 H Yes Male 27 3 0 40 
2-27 H Yes Male 32 3 0 48 
2-29 H Yes Male 66 2 0 48 
2-31 H Yes Male 20 3 0 48 
2-32 H Yes Female 28 2 0 36 
2-33 H Yes Male 59 3 0 41 
2-34 H Yes Male 27 2 0 29 
2-35 H Yes Female 65 2 0 48 
2-36 H Yes Male 32 3 0 52 
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5-10 MT Yes Female 31 2 0  
5-11 MT Yes Female 26 3 0  
6-05 H Yes Male 34 3 0 8 
6-06 H Yes Male 30 3 2 20 
6-07 H Yes Female 22 3 0 12 
6-08 H Yes Female 34 4 0 32 
6-09 H Yes Male 42 2 0 16 
6-10 H Yes Male 30 2 0 28 
6-11 H Yes Female 23 3 0 40 
6-13 H Yes Male 32 3 0 24 
6-14 H Yes Male 34 3 0 20 
6-15 H Yes Male 18 3 0 18 
6-16 H Yes Male 26 3 0 28 
6-23 H Yes Male 34 2 0 16 
7-01 H No Male 34 3 0 2 
7-02 H Yes Male 46 3 0 24 
7-03 H Yes Male 52 2 0 4 
7-04 H Yes Male 28 3 0 16 
7-05 H Yes Female 38 1 0 4 
7-06 H Yes Male 31 3 0 28 
7-07 H Yes Male 52 2 0 6 
7-08 H No Male 37 2 0 108 
7-09 H No Male 23 2 0 1 
7-10 H Yes Female 33 3 0 1 
7-11 H Yes Male 36 2 0 4 
1-04 H Yes Male 35 4 0 40 
1-05 H Yes Male 38 4 0 60 
1-06 MT Yes Female 15 2 0 50 
1-44 MT Yes Female 25 3 0 100 
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Table A4: General and clinical information of patients non-infected with T. b. 
gambiense. Table shows where patients were diagnosed, either at a hospital (H) or by 
mobile team (MT), if the patient were in an at-risk area (Yes) or not a high risk area 
(No) or unknown (UN). Patient’s sex and age were recorded. The patient’s general 
appearance at diagnosis (1, not ill; 2, mildly ill; 3, moderately ill; 4, gravely ill) and the 
duration of their main symptom (see table A8 for details of the bioclinical information) 
are shown. Females that were pregnant are shown as ‘Female’. 
 
ID Hospital 
(H) or 
Mobile 
Team (MT)  
Risk 
area? 
Male or 
Female 
Age General 
appearance 
2C01 H Yes Female 68 1 
2C02 H Yes Female 29 1 
2C03 H Yes Male 45 1 
2C04 H Yes Female 38 1 
2C05 H Yes Male 22 1 
2C06 H Yes Female 40 1 
2C08 H Yes Female 29 1 
2C09 H Yes Female 25 1 
2C20 H Yes Female 40 2 
2C21 H Yes Male 53 1 
2C23 H Yes Male 40 1 
2C24 H Yes Female 36 1 
2C26 H Yes Male 38 1 
2C36 H Yes Male 28 1 
2C57 H Yes Female 45 1 
2C58 H Yes Female 59 1 
2C59 H Yes Female 36 1 
2C60 H Yes Female 52 1 
2C61 H Yes Male 67 1 
2C62 H Yes Male 30 1 
3C04 H Yes Female 20 1 
3C05 H Yes Male 27 1 
3C17 H Yes Female 63 1 
3C18 H Yes Male 40 1 
3C19 H Yes Male 51 1 
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4C05 MT Yes Male 19 1 
4C15 MT Yes Female 29 1 
4C16 MT Yes Male 42 1 
5C01 MT Yes Male 40 1 
5C06 MT Yes Female 45 1 
5C28 MT Yes Male 33 2 
6C03 H Yes Male 49 1 
6C04 H Yes Male 44 1 
6C11 H Yes Female 30 1 
6C15 H Yes Female 48 1 
6C20 H Yes Female 34 1 
6C22 H Yes Female 38 1 
6C27 H Yes Female 26 1 
6C28 H Yes Male 56 1 
6C29 H Yes Male 47 1 
6C40 H Yes Male 30 1 
7C16 H No Female 26 1 
7C22 H No Female 41 1 
7C26 H No Male 56 1 
7C27 H No Female 40 1 
7C29 H No Female 43 1 
7C30 H Yes Female 50 1 
7C45 H No Female 55 1 
7C46 H Yes Male 45 1 
7C52 H No Female 35 1 
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Table A5: General and clinical information of patients infected with T. b. 
rhodesiense. Shaded ID codes represent the 1st stage patients. Table shows where 
patients were diagnosed, either at a hospital (H) or by mobile team (MT), if the patient 
were in an at-risk area (Yes) or not a high risk area (No) or unknown (NA). Patient’s 
sex and age were recorded. The patient’s general appearance at diagnosis (1, not ill; 2, 
mildly ill; 3, moderately ill; 4, gravely ill; 9, not known) and the duration of their main 
symptom (see table A9 for details of the bioclinical information) are shown. Females 
that were pregnant are shown as ‘Female’. 
 
ID Hospital (H) 
or Mobile 
Team (MT)  
Risk 
area? 
Male or 
Female 
Age General 
appearance 
Signs and 
symptoms 
Duration 
of main 
symptom 
(weeks) 
R004 MT NA Male 19 2 1  
R007 MT NA Female 60 1 0  
R035 MT NA Male 38 9 0  
R047 MT NA Male 32 2 0  
R061 MT NA Male 18 1 0  
        
R009 H Yes Male 22 3 7 3 
R014 MT NA Male 44 2 0  
R020 MT NA Male 32 4 1  
R022 MT NA Male 26 1 0  
R025 MT NA Female 42 2 0  
R039 MT NA Male 25 2 1  
R040 MT NA Male 37 2 1  
R041 MT NA Male 26 1 0  
R049 MT NA Male 41 1 0  
R052 MT NA Male 25 1 0  
R058 MT NA Female 27 4 1  
R060 MT NA Male 20 1 0  
R063 MT NA Male 24 1 0  
R065 MT NA Male 13 1 0  
R066 MT NA Male 58 1 0  
R067 MT NA Female 70 1 0  
R069 MT NA Female 60 1 0  
R070 MT NA Female 58 1 0  
10. APPENDIX                                                                                                            112 
 
 
R071 MT NA Female 18 1 0  
R072 MT NA Male 37 1 0  
 
 
Table A6: General and clinical information of non-infected patients. Table shows 
where patients were diagnosed, either at a hospital (H) or by mobile team (MT), if the 
patient were in an at-risk area (Yes) or not a high risk area (No) or unknown (NA). 
Patient’s sex and age were recorded. The patient’s general appearance at diagnosis (1, 
Nnt ill; 2, mildly ill; 3, moderately ill; 4, gravely ill) and the duration of their main 
symptom (see table A10 for details of the bioclinical information) are shown. Females 
that were pregnant are shown as ‘Female’. 
 
ID Hospital (H) 
or Mobile 
Team (MT)  
Risk 
area? 
Male or 
Female 
Age General 
appearance 
CR01 H Yes Male  1 
CR02 H Yes Male  1 
CR04 H Yes Male  1 
CR06 H Yes Female 24 1 
CR08 H Yes Male 20 1 
CR09 H Yes Female 18 1 
CR20 MT NA Female 21 4 
CR40 MT NA Female 22 1 
CR41 MT NA Female 64 1 
CR43 MT NA Female 48 1 
CR48 MT NA Female 22 1 
CR49 MT NA Female 39 1 
CR50 MT NA Male 25 1 
CR52 MT NA Female 21 1 
CR59 MT NA Male 48 1 
CR61 MT NA Female 28 1 
CR62 MT NA Female 21 1 
CR63 MT NA Female 23 1 
CR64 MT NA Female 20 1 
CR68 MT NA Female 27 1 
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Table A7: Bioclinical information of patients infected with T. b. gambiense. Shaded 
ID codes represent the 1st stage patients. Table shows results from the CATT test (1, 
positive, 0, negative) and the highest blood titration which still gave a positive result 
(expressed as fraction). Results from microscope examination of the patient’s blood for 
trypanosomes (1, positive; 0, negative, blank, procedure was not carried out), and 
microscope examination after CTC and mAECT (centrifugation techniques) and lymph 
node puncture. Cerebrospinal fluid was also examined for trypanosomes (1, positive; 0, 
negative) and white and red blood cells were counted. Blank spaces represent unknown 
or not applicable data.  
 
  
  
 
BLOOD 
LYM
PH 
NOD
E 
 
CEREBROSPINAL FLUID 
 
ID 
 
CATT 
1/4 
 
PATIENTS 
Highest 
positive 
titration 
 
WET 
 
CTC 
 
MAEC
T 
 
Punct
ure 
 
Direct 
examin
ation 
 
Double 
Centrifu
gation 
 
Modified 
Simple 
Centrifu
gation 
 
Numbe
r of 
White 
Blood 
cells 
/µl 
 
Number 
of Red 
Blood 
Cells/µl 
4-01 1 1/32       1 0 0   4 0 
4-02 1 1/32       1 0 0   2 0 
4-06 1 1/32       1 0 0   5 0 
5-03 1 1/32     0 1 0     5 0 
5-04 1 1/32     1 1 0     1 0 
5-05 1 1/32   1 1   0     4 0 
1-13 2         1 0     2 0 
1-18 2     0   1 0     4 50 
1-20 1 1/32   0 1 0 0     1 0 
1-21       0 1   0     4 0 
            2-21 1 1/32 0 1 0   1     1232 0 
2-24 1 1/32 0     1 1     435 0 
2-26 1 1/32 0     1 1     231 0 
2-27 1 1/32 0     1 1     305 0 
2-29 1 1/32 0 1     1     180 0 
2-31 1 1/32 0 0 0   1     611 0 
2-32 1 1/32 0     1 1     352 0 
2-33 1 1/32 0 1 1   1     819 0 
2-34 1 1/32 0 1     0     7 0 
2-35 1 1/32 0 1     1     530 0 
2-36 1 1/32 0 0 0 1 1     388 0 
5-10 1 1/32   0 1   0     74 0 
5-11 1 1/32   1   1 1     147 0 
6-05 1 1/16       1 0     575 0 
6-06 1 1/32   0 0   0   1 187 0 
6-07 1 1/16   0 0 0 0   1 176 0 
6-08 1 1/16       1 1     500 0 
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6-09 1 1/64       1 0     380 0 
6-10 1 1/32       1 1     1200 0 
6-11 1 1/32       1 1     750 0 
6-13 1 1/64   0 1   1     800 0 
6-14 1 1/32       1 0     240 0 
6-15 1 1/16       1 0     75 0 
6-16 1 1/32       1 0     77 0 
6-23 1 1/64   0 1 0 1     972 0 
7-01 1 1/32   0   1 1   1 369 0 
7-02 1 1/8   0 0   0   1 176 0 
7-03 1 1/32       1 1     82 0 
7-04 1 1/16       1 1     353 0 
7-05 1 1/32       1 0     191 0 
7-06 1 1/32       1 0   1 128 0 
7-07 1 >1/32   1   0 0     16 0 
7-08 1 1/16   0 0 0 1     215 0 
7-09 1 >1/32       1 0     895 0 
7-10 1 1/16   0 1   1     152 3 
7-11 1 >1/32       1 0     386 0 
1-04 2         1 0   0 400 0 
1-05 2     0 0   0   1 100   
1-06 1 >1/32       1 1     20   
1-44 2     1   1 0     13 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10. APPENDIX                                                                                                            115 
 
 
Table A8: Bioclinical information of non-infected patients. Table shows results from 
the CATT test (1, positive, 0, negative) and the highest blood titration tried which still 
gave a negative result (expressed as fraction). Results from microscope examination of 
the patient’s blood for trypanosomes (1, positive; 0, negative, blank, procedure was not 
carried out), and microscope examination after CTC and mAECT (centrifugation 
techniques) and lymph node puncture. Cerebrospinal fluid was also examined for 
trypanosomes (1, positive; 0, negative) and white and red blood cells were counted. 
Blank spaces represent unknown or not applicable data.  
  
CATT 
 
 
 
BLOOD 
 
 
 
LYMPH 
NODE 
 
 
ID 
 
CATT 
 
CATT 
1/4 
 
 
CONTROLS 
Lowest 
dilution 
tested 
 
WET 
 
CTC 
 
MAECT 
 
Puncture 
 
Thin Blood 
Film 
2C01 0 0 0 0 0 0 0 0 
2C02 0 0 1/4  0 0   
2C03 0 0 1/4  0 0   
2C04 0 0 1/4 0 0 0   
2C05 0 0 1/4 0 0 0   
2C06 0 0 1/4 0 0 0   
2C08 0 0 1/4 0 0 0 0  
2C09 0 0 1/4 0 0 0   
2C20 0 0 1/4 0 0 0 0  
2C21 0 0 1/4 0 0 0   
2C23 0 0 1/4 0 0 0 0  
2C24 0 0 1/4 0 0 0 0  
2C26 0 0 1/4 0 0 0 0  
2C36 0 0 1/4 0 0 0   
2C57 0 0 1/4  0 0   
2C58 0 0 1/4 0 0 0   
2C59 0 0 1/4  0 0   
2C60 0 0 1/4  0 0   
2C61 0 0 1/4 0 0 0   
2C62 0 0 1/4 0 0 0   
3C04 0 0 1/00  0 0   
3C05 0 0 1/1 0 0 0   
3C17 0 0 1/1 0 0 0   
3C18 0 0 1/1 0 0 0   
3C19 0 0 1/1 0 0 0   
4C05 0 0 0  0 0   
4C15 0 0 0  0 0   
4C16 0 0 0  0 0   
5C01 0 0 0   0   
5C06 0 0 0   0   
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5C28 0 0 0  0 0 0  
6C03 0 0 0  0 0   
6C04 0 0 0  0 0   
6C11 0 0 0  0 0   
6C15 0 0 0  0 0   
6C20 0 0 0  0 0   
6C22 0 0 0  0 0   
6C27 0 0 0  0 0   
6C28 0 0 0  0 0   
6C29 0 0 0  0 0   
6C40 0 0 1/2  0 0   
7C16 0 0 0  0 0   
7C22 0 0 0  0 0   
7C26 0 0 0   0   
7C27 0 0 0   0   
7C29 0 0 0   0   
7C30 0 0 0   0   
7C45 0 0 0   0   
7C46 0 0    0   
7C52 0 0 1/2   0   
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Table A9: Bioclinical information of patients infected with T. b. rhodesiense. 
Shaded ID codes represent the 1st stage patients. Results from microscope examination 
of the patient’s blood for trypanosomes (1, positive; 0, negative, blank, procedure was 
not carried out), and microscope examination after CTC and mAECT (centrifugation 
techniques) and lymph node puncture. Cerebrospinal fluid was also examined for 
trypanosomes (1, positive; 0, negative) and white and red blood cells were counted. 
Blank spaces represent unknown or not applicable data. Extra information was included 
for R035, which had a weakly positive/negative CATT result. 
 
  
  
 
BLOOD 
 
CEREBROSPINAL FLUID 
 
ID 
 
Thin 
blood 
film 
 
WET 
 
CTC 
 
MAECT 
 
Direct 
examination 
 
Modified 
Simple 
Centrifugation 
 
Number 
of White 
Blood 
cells /µl 
 
Number of 
Red Blood 
Cells/µl 
R004 1   1   0 0 3  
R007   1 1   0      
R035 0 0 1   0 0 5 0 
R047   1 1   0 0 1   
R061   1 1   0 0 1   
         
R009   1 1   1 1   0 
R014 1 1 1   1 1 35 0 
R020   1 1   1   349 0 
R022   2 1   1   1002 0 
R025   2 1   1   35 0 
R039   1 1   1   57 0 
R040   2 1   0 0 400   
R041   2 1   1   9   
R049   1 1   1   19   
R052   0 2 1 1   14   
R058   9 9   1   159   
R060   2 1   0 1 15   
R063   1 1   0 1 26   
R065 0 1 1 1 1 1 10   
R066   1 1   1   55   
R067   1 1   1   10   
R069   1 1   1   10   
R070   1 1   1 1 50   
R071   1 1   1       
R072   0 1   0 1 10   
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Table A10: Bioclinical information of non-infected patients. Table shows results 
from the CATT test (1, positive, 0, negative) and the highest blood titration tried which 
still gave a negative result (expressed as fraction). Results from microscope examination 
of the patient’s blood for trypanosomes (1, positive; 0, negative, blank, procedure was 
not carried out), and microscope examination after CTC and mAECT (centrifugation 
techniques) and lymph node puncture. Cerebrospinal fluid was also examined for 
trypanosomes (1, positive; 0, negative).  
 
  
CATT 
 
 
BLOOD 
 
 
 
LYMPH NODE 
 
ID 
 
CATT 
 
CATT 
1/4 
 
WET 
 
CTC 
 
MAECT 
 
Puncture 
 
Thin Blood 
Film 
CR01   0 0 0   
CR02   0 0 0   
CR04   0 0 0   
CR06   0 0 0   
CR08   0 0 0   
CR09   0 0 0   
CR20 0  0 0 0 0  
CR40 0  0 0 0 0 0 
CR41 0  0 0 0 0 0 
CR43 0  0 0 0 0 0 
CR48 0 0 0 0 0 0 0 
CR49 0 0 0 0 0 0 0 
CR50 0  0 0 0 0 0 
CR52 0  0 0 0 0 0 
CR59 0 0 0 0 0 0 0 
CR61 0 0 0 0 0 0 0 
CR62 0 0 0 0 0 0 0 
CR63 0 0 0 0 0 0 0 
CR64 0 0 0 0 0 0 0 
CR68     0 0      
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